View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2013	Feb. 24, 2014	Jun. 30, 2013
Document and Entity Information
Entity Registrant Name	AMICUS THERAPEUTICS INC
Entity Central Index Key	0001178879
Document Type	10-K
Document Period End Date	Dec. 31, 2013
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 53,244,333
Entity Common Stock, Shares Outstanding		62,263,325
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 43,640	$ 33,971
Investments in marketable securities	38,360	65,151
Receivable due from GSK	759	3,225
Prepaid expenses and other current assets	5,519	2,270
Total current assets	88,278	104,617
Property and equipment, less accumulated depreciation and amortization of $8,501 and $9,973 at December 31, 2012 and 2013, respectively	4,120	5,029
In-process research & development	23,000
Goodwill	11,613
Other non-current assets	552	442
Total Assets	127,563	110,088
Current liabilities:
Accounts payable and accrued expenses	10,162	8,845
Current portion of secured loan	299	398
Total current liabilities	10,461	9,243
Deferred reimbursements	36,677	30,418
Warrant liability		908
Secured loan, less current portion	14,174	299
Contingent consideration payable	10,600
Deferred tax liability	9,186
Other non-current liability	714
Commitments and contingencies
Stockholders' equity:
Common stock, $.01 par value, 125,000,000 shares authorized, 49,631,672 shares issued and outstanding at December 31, 2012, 61,975,416 shares issued and outstanding at December 31, 2013	679	556
Additional paid-in capital	423,593	387,539
Accumulated other comprehensive income	1	14
Deficit accumulated during the development stage	(378,522)	(318,889)
Total stockholders' equity	45,751	69,220
Total Liabilities and Stockholders' Equity	$ 127,563	$ 110,088

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Consolidated Balance Sheets
Accumulated depreciation and amortization of property and equipment (in dollars)	$ 9,973	$ 8,501
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	61,975,416	49,631,672
Common stock, shares outstanding	61,975,416	49,631,672

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended			143 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Revenue:
Research revenue	$ 363	$ 11,591	$ 14,794	$ 57,856
Collaboration and milestone revenue		6,820	6,640	64,382
Total revenue	363	18,411	21,434	122,238
Operating Expenses:
Research and development	41,944	50,273	50,856	357,837
General and administrative	18,893	19,364	19,880	151,506
Restructuring charges	1,988			3,510
Impairment of leasehold improvements				1,030
Depreciation and amortization	1,719	1,705	1,585	13,487
In-process research and development				418
Total operating expenses	64,544	71,342	72,321	527,788
Loss from operations	(64,181)	(52,931)	(50,887)	(405,550)
Other income (expenses):
Interest income	174	316	160	14,563
Interest expense	(46)	(89)	(148)	(2,468)
Change in fair value of warrant liability	908	653	2,764	2,461
Other income		21	70	252
Loss before income tax benefit	(63,145)	(52,030)	(48,041)	(390,742)
Income tax benefit	3,512	3,245	3,629	12,220
Net loss	(59,633)	(48,785)	(44,412)	(378,522)
Deemed dividend				(19,424)
Preferred stock accretion				(802)
Net loss attributable to common stockholders	$ (59,633)	$ (48,785)	$ (44,412)	$ (398,748)
Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)	$ (1.16)	$ (1.07)	$ (1.28)
Weighted-average common shares outstanding - basic and diluted (in shares)	51,286,059	45,565,217	34,569,642

Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

143 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Consolidated Statements of Comprehensive Loss

Net loss

$ (59,633)

$ (48,785)

$ (44,412)

$ (378,522)

Other comprehensive income/(loss):

Unrealized gain/ (loss) on available-for-sale securities

(13)

Other comprehensive (loss)/income before income taxes

(13)

Provision for income taxes related to other comprehensive (loss)/income items

^[1]

Other comprehensive (loss)/income

(13)

Comprehensive loss

$ (59,646)

$ (48,775)

$ (44,380)

$ (378,521)

[1]	Taxes have not been accrued on unrealized gain on securities as the Company is in a loss position for all periods presented.

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Changes in Stockholders' (Deficiency)/Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Other Comprehensive Gain/ (Loss)	Deferred Compensation	Deficit Accumulated During the Development Stage
Balance at Dec. 31, 2002	$ (1,249)	$ 23	$ 685		$ (182)	$ (1,775)
Balance (in shares) at Dec. 31, 2002		307,204
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net (in shares)		333
Deferred compensation			14		(14)
Amortization of deferred compensation	70				70
Issuance of warrants	210		210
Issuance of stock options to consultants	4		4
Accretion of redeemable convertible preferred stock	(17)		(17)
Beneficial conversion on issuance of Series C redeemable convertible preferred stock	41		41
Comprehensive (Loss)/ Income:
Net loss	(6,768)					(6,768)
Balance at Dec. 31, 2003	(7,709)	$ 23	937		(126)	(8,543)
Balance (in shares) at Dec. 31, 2003		307,537
Increase (Decrease) in Stockholders' Equity
Deferred compensation			68		(68)
Amortization of deferred compensation	60				60
Issuance of stock options to consultants	16		16
Interest waived on converted convertible notes	193		193
Accretion of redeemable convertible preferred stock	(126)		(126)
Beneficial conversion on issuance of Series C redeemable convertible preferred stock	95		95
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	(9)			$ (9)
Net loss	(8,807)					(8,807)
Balance at Dec. 31, 2004	(16,287)	$ 23	1,183	(9)	(134)	(17,350)
Balance (in shares) at Dec. 31, 2004		307,537
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net	24	$ 7	17
Stock issued from exercise of stock options, net (in shares)		97,156
Stock issued from exercise of warrants	75	$ 10	65
Stock issued from exercise of warrants (in shares)		133,332
Deferred compensation			2,778		(2,778)
Amortization of deferred compensation	365				365
Issuance of stock options to consultants	112		112
Accretion of redeemable convertible preferred stock	(139)		(139)
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	(7)			(7)
Net loss	(19,972)					(19,972)
Balance at Dec. 31, 2005	(35,829)	$ 40	4,016	(16)	(2,547)	(37,322)
Balance (in shares) at Dec. 31, 2005		538,025
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net	158	$ 20	138
Stock issued from exercise of stock options, net (in shares)		265,801
Stock issued for license payment	1,220	$ 10	1,210
Stock issued for license payment (in shares)		133,333
Reversal of deferred compensation upon adoption of FAS 123(R)			(2,547)		$ 2,547
Issuance of stock options to consultants	476		476
Stock-based compensation	2,816		2,816
Stock-based compensation (in shares)		53,333
Accretion of redeemable convertible preferred stock	(159)		(159)
Reclassification of warrant liability upon exercise of Series B redeemable convertible preferred stock warrants	117		117
Beneficial conversion on issuance of Series C redeemable convertible preferred stock	19,424		19,424
Beneficial conversion charge (deemed dividend) on issuance of Series C redeemable convertible preferred stock	(19,424)		(19,424)
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	31			31
Net loss	(46,345)					(46,345)
Balance at Dec. 31, 2006	(77,515)	$ 70	6,067	15		(83,667)
Balance (in shares) at Dec. 31, 2006		990,492
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	68,145	$ 50	68,095
Issuance of common stock (in shares)		5,000,000
Stock issued from conversion of preferred shares	148,591	$ 162	148,429
Stock issued from conversion of preferred shares (in shares)		16,112,721
Stock issued from exercise of stock options, net	458	$ 3	455
Stock issued from exercise of stock options, net (in shares)		305,518
Issuance of stock options to consultants	162		162
Stock-based compensation	3,823		3,823
Accretion of redeemable convertible preferred stock	(351)		(351)
Charge for warrant liability	758		758
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	393			393
Net loss	(41,167)					(41,167)
Balance at Dec. 31, 2007	103,297	$ 285	227,438	408		(124,834)
Balance (in shares) at Dec. 31, 2007		22,408,731
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net	530	$ 2	528
Stock issued from exercise of stock options, net (in shares)		225,980
Stock-based compensation	6,446		6,446
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	125			125
Net loss	(39,355)					(39,355)
Balance at Dec. 31, 2008	71,043	$ 287	234,412	533		(164,189)
Balance (in shares) at Dec. 31, 2008		22,634,711
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net	60		60
Stock issued from exercise of stock options, net (in shares)		37,716
Stock-based compensation	7,787		7,787
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	(490)			(490)
Net loss	(6,567)					(6,567)
Balance at Dec. 31, 2009	71,833	$ 287	242,259	43		(170,756)
Balance (in shares) at Dec. 31, 2009		22,672,427
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	13,830	$ 50	13,780
Issuance of common stock (in shares)		4,946,525
Stock issued from collaboration agreement	28,083	$ 69	28,014
Stock issued from collaboration agreement (in shares)		6,866,245
Stock issued from exercise of stock options, net	9		9
Stock issued from exercise of stock options, net (in shares)		23,735
Stock-based compensation	6,186		6,186
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	(71)			(71)
Net loss	(54,936)					(54,936)
Balance at Dec. 31, 2010	64,934	$ 406	290,248	(28)		(225,692)
Balance (in shares) at Dec. 31, 2010		34,508,932
Increase (Decrease) in Stockholders' Equity
Stock issued from exercise of stock options, net	360	$ 1	359
Stock issued from exercise of stock options, net (in shares)		145,274
Stock-based compensation	8,678		8,678
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	32			32
Net loss	(44,412)					(44,412)
Balance at Dec. 31, 2011	$ 29,592	$ 407	299,285	4		(270,104)
Balance (in shares) at Dec. 31, 2011	34,654,206	34,654,206
Increase (Decrease) in Stockholders' Equity
Issuance of common stock	$ 62,055	$ 115	61,940
Issuance of common stock (in shares)		11,500,000
Stock issued from collaboration agreement	18,140	$ 29	18,111
Stock issued from collaboration agreement (in shares)		2,949,581
Stock issued from exercise of stock options, net	1,630	$ 4	1,626
Stock issued from exercise of stock options, net (in shares)		436,952
Stock issued from exercise of warrants	387	$ 1	386
Stock issued from exercise of warrants (in shares)		90,933
Stock-based compensation	6,191		6,191
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	10			10
Net loss	(48,785)					(48,785)
Balance at Dec. 31, 2012	$ 69,220	$ 556	387,539	14		(318,889)
Balance (in shares) at Dec. 31, 2012	49,631,672	49,631,672
Increase (Decrease) in Stockholders' Equity
Stock and warrants issued in financing	$ 15,000	$ 75	14,925
Stock and warrants issued in financing (in shares)		7,500,000
Stock issued for Callidus acquisition	15,000	$ 48	14,952
Stock issued for Callidus acquisition (in shares)		4,843,744
Stock-based compensation	6,177		6,177
Comprehensive (Loss)/ Income:
Unrealized holding gain (loss) on available-for-sale securities	(13)			(13)
Net loss	(59,633)					(59,633)
Balance at Dec. 31, 2013	$ 45,751	$ 679	$ 423,593	$ 1		$ (378,522)
Balance (in shares) at Dec. 31, 2013	61,975,416	61,975,416

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended			143 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Operating activities
Net loss	$ (59,633)	$ (48,785)	$ (44,412)	$ (378,522)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense				525
Depreciation and amortization	1,719	1,705	1,585	13,487
Amortization of non-cash compensation				522
Stock-based compensation	6,177	6,191	8,679	48,106
Non-cash charge for stock based compensation issued to consultants				853
Restructuring charges	1,988			3,510
Change in fair value of warrant liability	(908)	(653)	(2,764)	(2,461)
Loss on disposal of asset		28		388
Stock-based license payment				1,220
Impairment of leasehold improvements				1,030
Non-cash charge for in process research and development				418
Beneficial conversion feature related to bridge financing				135
Changes in operating assets and liabilities:
Receivable due from GSK	2,466	1,818	(5,043)	(759)
Prepaid expenses and other current assets	(3,249)	3,633	(3,667)	(5,519)
Other non-current assets		267	(442)	(466)
Account payable and accrued expenses	(613)	(863)	1,418	6,710
Deferred reimbursements	6,259	2,915	(4,776)	36,677
Net cash used in operating activities	(45,794)	(33,744)	(49,422)	(274,146)
Investing activities
Sale and redemption of marketable securities	83,337	83,352	98,474	838,779
Purchases of marketable securities	(56,559)	(118,459)	(50,602)	(877,254)
Purchases of property and equipment	(695)	(4,324)	(1,420)	(18,908)
Net cash provided by/ (used in) investing activities	26,083	(39,431)	46,452	(57,383)
Financing activities
Proceeds from the issuance of preferred stock, net of issuance costs				143,022
Proceeds from issuance of common stock and warrants, net of issuance costs	15,000	80,195		208,441
Proceeds from the issuance of convertible notes				5,000
Payments of capital lease obligations			(40)	(5,587)
Payments of secured loan agreement	(398)	(1,342)	(1,253)	(4,454)
Payments related to deferred financing	(110)			(110)
Proceeds from exercise of stock options		1,630	359	3,341
Proceeds from exercise of warrants (common and preferred)				264
Proceeds from capital asset financing arrangement				5,611
Proceeds from secured loan agreement	14,888	995		19,641
Net cash (used in)/ provided by financing activities	29,380	81,478	(934)	375,169
Net (decrease)/ increase in cash and cash equivalents	9,669	8,303	(3,904)	43,640
Cash and cash equivalents at beginning of year/period	33,971	25,668	29,572
Cash and cash equivalents at end of year/period	43,640	33,971	25,668	43,640
Supplemental disclosures of cash flow information
Cash paid during the period for interest	$ 30	84	$ 149	2,147
Non-cash activities
Conversion of warrants to common stock		$ 386		386
Conversion of notes payable to Series B redeemable convertible				5,000
Conversion of preferred stock to common stock				148,951
Accretion of redeemable convertible preferred stock				802
Beneficial conversion feature related to issuance of the additional issuance of Series C redeemable convertible preferred stock				$ 19,424

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2013
Description of Business
Description of Business	1. Description of Business *Corporate Information, Status of Operations, and Management Plans* Amicus Therapeutics, Inc. ("the Company") was incorporated on February 4, 2002 in Delaware and is a biopharmaceutical company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage diseases ("LSDs"). The Company's lead program is migalastat HCl for Fabry disease. Migalastat HCl is a novel, small molecule pharmacological chaperone in development as a monotherapy and in combination with enzyme replacement therapy "(ERT") for Fabry disease. The Company is leveraging its Chaperone-Advanced Replacement Therapy, or CHART™ platform to develop next-generation therapies that combine pharmacological chaperones with enzyme therapies for Pompe, Mucopolysaccharidosis Type I ("MPS I") and Gaucher diseases. Current CHART™ programs for Pompe disease include the pharmacological chaperone AT2220 (duvoglustat HCl) co-administered with currently marketed Pompe ERTs (Myozyme®/Lumizyme®), as well as AT2220 co-formulated with a proprietary Pompe ERT. The Company's activities since inception have consisted principally of raising capital, establishing facilities, and performing research and development. Accordingly, the Company is considered to be in the development stage. In November 2013, the Company completed the acquisition of Callidus Biopharma, Inc. ("Callidus") through an Agreement and Plan of Merger ("the Merger Agreement") between the Company's wholly owned subsidiary, CB Acquisition Corp ("CB") and Callidus whereby CB merged with and into Callidus with Callidus becoming the surviving corporation of the merger. As a result of the merger, Callidus became a wholly owned subsidiary of Amicus. For further information, see "— Note 3. Acquisition of Callidus Biopharma,Inc. Callidus was a privately-held biologics company focused on developing best-in-class enzyme replacement therapies (ERTs) for lysosomal storage diseases (LSDs). Callidus' lead ERT is a recombinant human acid-alpha glucosidase (rhGAA, called "AT-B200") for Pompe disease in late preclinical development In November 2013, Amicus entered into the Revised Agreement (the "Revised Agreement") with GlaxoSmithKline plc ("GSK"), pursuant to which Amicus has obtained global rights to develop and commercialize migalastat HCl as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the Expanded Agreement entered into between Amicus and GSK in July 2012. Under the terms of the Revised Agreement, there is no upfront payment from Amicus to GSK. For the next-generation Fabry ERT (migalastat HCl co-formulated with ERT), GSK is eligible to receive single-digit royalties on net sales in eight major markets outside the U.S. For migalastat HCl monotherapy, GSK is eligible to receive post-approval and sales-based milestones, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In November 2013, the Company entered into a securities purchase agreement (the "2013 SPA") with GSK and certain entities controlled by Redmile Group, LLC for the private placement of a) shares of the Company's common stock and b) a combination of shares of the Company's common stock and warrants to purchase shares of the Company's common stock. The warrants have a term of one year and are exercisable between July 1, 2014 and June 30, 2015 at an exercise price of $2.50 per share. The aggregate offer proceeds were $15 million and GSK's resulting equity stake in the Company was 17.6% at December 31, 2013. In September 2013, the Company entered into a collaboration agreement with Biogen Idec ("Biogen") to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. The collaboration will build upon preclinical studies at the Company and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase ("GCase") in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease. Under terms of the multi-year agreement, the Company and Biogen will collaborate in the discovery of a new class of small molecules that target the GCase enzyme, for further development and commercialization by Biogen. Biogen will be responsible for funding all discovery, development, and commercialization activities. In addition the Company will be reimbursed for all full-time employees working on the project. The Company is also eligible to receive development and regulatory milestones, as well as modest royalties on global net sales. For further information, see "— Note 15. Collaborative Agreements" The Company had an accumulated deficit of approximately $378.5 million at December 31, 2013 and anticipates incurring losses through the fiscal year ending December 31, 2014 and beyond. The Company has not yet generated commercial sales revenue and has been able to fund its operating losses to date through the sale of its redeemable convertible preferred stock, issuance of convertible notes, net proceeds from its initial public offering ("IPO") and subsequent stock offerings, payments from partners during the terms of the collaboration agreements and other financing arrangements. In March 2010, the Company sold 4.95 million shares of its common stock and also sold warrants to purchase 1.9 million shares of common stock in a registered direct offering to a select group of institutional investors for net proceeds of $17.1 million. In October 2010, the Company sold 6.87 million shares of its common stock as part of the Original Collaboration Agreement with GSK for proceeds of $31.0 million. In March 2012, the Company sold 11.5 million shares of its common stock in a stock offering for net proceeds of $62.0 million. In July 2012, the Company sold 2.9 million shares of its common stock as part of the Expanded Collaboration Agreement with GSK for proceeds of $18.6 million. In November 2013, the Company sold 7.5 million shares of its common stock and also sold warrants to purchase 1.6 million shares of its common stock in a private placement for proceeds of $15 million. The Company believes that its existing cash and cash equivalents and short-term investments will be sufficient to cover its cash flow requirements for 2014.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. GAAP and include all adjustments necessary for the fair presentation of the Company's financial position for the periods presented.

Consolidation

The financial statements include the accounts of Amicus Therapeutics, Inc. and its wholly owned subsidiaries, Amicus Therapeutics UK Limited and Callidus Biopharma, Inc. All significant intercompany transactions and balances are eliminated in consolidation. These subsidiaries are not material to the overall financial statements of the Company.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Cash, Money Market Funds, and Marketable Securities

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.

Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within comprehensive income/(loss) in the statements of comprehensive loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations or other observable inputs. See "— Note 6. Cash, Money Market Funds and Marketable Securities" for a summary of available-for-sale securities as of December 31, 2013 and 2012.

Concentration of Credit Risk

The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated over the estimated useful lives of the respective assets, which range from three to five years, or the lesser of the related initial term of the lease or useful life for leasehold improvements. Assets under capital leases are amortized over the terms of the related leases or their estimated useful lives, whichever is shorter.

The initial cost of property and equipment consists of its purchase price and any directly attributable costs of bringing the asset to its working condition and location for its intended use. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to income in the period in which the costs are incurred. Major replacements, improvements and additions are capitalized in accordance with Company policy.

Revenue Recognition

The Company recognizes revenue when amounts are realized or realizable and earned. Revenue is considered realizable and earned when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price is fixed or determinable; and (4) collection of the amounts due are reasonably assured.

In multiple element arrangements, revenue is allocated to each separate unit of accounting and each deliverable in an arrangement is evaluated to determine whether it represents separate units of accounting. A deliverable constitutes a separate unit of accounting when it has standalone value and there is no general right of return for the delivered elements. In instances when the aforementioned criteria are not met, the deliverable is combined with the undelivered elements and the allocation of the arrangement consideration and revenue recognition is determined for the combined unit as a single unit of accounting. Allocation of the consideration is determined at arrangement inception on the basis of each unit's relative selling price. In instances where there is determined to be a single unit of accounting, the total consideration is applied as revenue for the single unit of accounting and is recognized over the period of inception through the date where the last deliverable within the single unit of accounting is expected to be delivered.

The Company's current revenue recognition policies, which were applied in fiscal 2010, provide that, when a collaboration arrangement contains multiple deliverables, such as license and research and development services, the Company allocates revenue to each separate unit of accounting based on a selling price hierarchy. The selling price hierarchy for a deliverable is based on (i) its vendor specific objective evidence ("VSOE") if available, (ii) third party evidence ("TPE") if VSOE is not available, or (iii) best estimated selling price ("BESP") if neither VSOE nor TPE is available. The Company would establish the VSOE of selling price using the price charged for a deliverable when sold separately. The TPE of selling price would be established by evaluating largely similar and interchangeable competitor products or services in standalone sales to similarly situated customers. The BESP would be established considering internal factors such as an internal pricing analysis or an income approach using a discounted cash flow model.

The Company also considers the impact of potential future payments it makes in its role as a vendor to its customers and evaluates if these potential future payments could be a reduction of revenue from that customer. If the potential future payments to the customer are:

•

a payment for an identifiable benefit; and

•

the identifiable benefit is separable from the existing relationship between the Company and its customer; and

•

the identifiable benefit can be obtained from a party other than the customer; and

•

the Company can reasonably estimate the fair value of the identifiable benefit

then the payments are accounted for separate from the revenue received from that customer. If, however, all these criteria are not satisfied, then the payments are treated as a reduction of revenue from that customer.

If the Company determines that any potential future payments to its customers are to be considered as a reduction of revenue, it must evaluate if the total amount of revenue to be received under the arrangement is fixed and determinable. If the total amount of revenue is not fixed and determinable due to the uncertain nature of the potential future payments to the customer, then any customer payments cannot be recognized as revenue until the total arrangement consideration becomes fixed and determinable.

The reimbursements for research and development costs under collaboration agreements that meet the criteria for revenue recognition are included in Research Revenue and the costs associated with these reimbursable amounts are included in research and development expenses.

In order to determine the revenue recognition for contingent milestones, the Company evaluates the contingent milestones using the criteria as provided by the Financial Accounting Standards Boards ("FASB") guidance on the milestone method of revenue recognition at the inception of a collaboration agreement. The criteria requires that (i) the Company determines if the milestone is commensurate with either its performance to achieve the milestone or the enhancement of value resulting from the Company's activities to achieve the milestone, (ii) the milestone be related to past performance, and (iii) the milestone be reasonable relative to all deliverable and payment terms of the collaboration arrangement. If these criteria are met then the contingent milestones can be considered as substantive milestones and will be recognized as revenue in the period that the milestone is achieved.

Fair Value Measurements

The Company records certain asset and liability balances under the fair value measurements as defined by the FASB guidance. Current FASB fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions that market participants assumptions would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy).

Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which is typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.

Research and Development Costs

Research and development costs are expensed as incurred. Research and development expense consists primarily of costs related to personnel, including salaries and other personnel related expenses, consulting fees and the cost of facilities and support services used in drug development. Assets acquired that are used for research and development and have no future alternative use are expensed as in-process research and development.

Interest Income and Interest Expense

Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and secured debt.

Other Income and Expenses

Other income includes funds received from the U.S. Treasury Department in 2011 for the Qualified Therapeutic Discovery Projects tax credit and grant program and the gain on sale of certain fixed assets in 2012. Other expenses include costs directly attributable to a planned offering of the Company's securities that were subsequently withdrawn during 2006 and the losses on the disposal of certain fixed assets.

Income Taxes

The Company accounts for income taxes under the liability method. Under this method deferred income tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities and for operating losses and tax credit carry forwards, using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded if it is "more likely than not" that a portion or all of a deferred tax asset will not be realized.

Other Comprehensive Income/ (Loss)

Components of other comprehensive income/ (loss) include unrealized gains and losses on available-for-sale securities and are included in the statements of comprehensive loss.

Leases

In the ordinary course of business, the Company enters into lease agreements for office space as well as leases for certain property and equipment. The leases have varying terms and expirations and have provisions to extend or renew the lease agreement, among other terms and conditions, as negotiated. Once the agreement is executed, the lease is assessed to determine whether the lease qualifies as a capital or operating lease.

When a non-cancelable operating lease includes any fixed escalation clauses and lease incentives for rent holidays or build-out contributions, rent expense is recognized on a straight-line basis over the initial term of the lease. The excess between the average rental amount charged to expense and amounts payable under the lease is recorded in accrued expenses.

Stock-Based Compensation

At December 31, 2013, the Company had three stock-based employee compensation plans, which are described more fully in "— Note 9. Stockholders' Equity." The Company applies the fair value method of measuring stock-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award.

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

The Company calculates net loss per share as a measurement of the Company's performance while giving effect to all dilutive potential common shares that were outstanding during the reporting period. The Company had a net loss for all periods presented; accordingly, the inclusion of common stock options and warrants would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted earnings per share are the same.

The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share (in thousands except share amounts):

	Years Ended December 31,

	2011			2012			2013
Historical
Numerator:
Net loss attributable to common stockholders	$	(44,412	)	$	(48,785	)	$	(59,633	)




Denominator:
Weighted average common shares outstanding — basic and diluted		34,569,642			45,565,217			51,286,059

Dilutive common stock equivalents would include the dilutive effect of common stock options and warrants for common stock equivalents. Potentially dilutive common stock equivalents totaled approximately 8.5 million, 9.4 million and 12.0 million for the years ended December 31, 2011, 2012 and 2013, respectively. Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.

Dividends

The Company has not paid cash dividends on its capital stock to date. The Company currently intends to retain its future earnings, if any, to fund the development and growth of the business and does not foresee payment of a dividend in any upcoming fiscal period.

Segment Information

The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker who comprehensively manages the entire business. The Company does not operate any separate lines of business or separate business entities with respect to its products. Accordingly, the Company does not accumulate discrete financial information with respect to separate service lines and does not have separately reportable segments.

Business Combinations

The Company allocates the purchase price of acquired businesses to the tangible and intangible assets acquired and liabilities assumed based upon their estimated fair values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets and in-process research and development (IPR&D). In connection with the purchase price allocations for acquisitions, the Company estimates the fair value of contingent payments utilizing a probability-based income approach inclusive of an estimated discount rate.

Contingent Consideration Payable

The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is shown as a non-current liability on the Company's consolidated balance sheets. Changes in the fair value of the contingent acquisition consideration payable will be determined each period end and recorded on the consolidated statements of operations.

Intangible Assets and Goodwill

The Company records goodwill in a business combination when the total consideration exceeds the fair value of the net tangible and identifiable intangible assets acquired. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset, or abandoned, at which point the intangible asset will be written off or partially impaired. Goodwill and indefinite lived intangible assets are assessed annually for impairment and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value.

Recent Accounting Pronouncements

In July 2013, the FASB issued an update that clarified existing guidance on the presentation of unrecognized tax benefits when various qualifying tax benefit carryforwards exist, including when the unrecognized tax benefit should be presented as a reduction to deferred tax assets or as a liability. This update is required to be adopted for all annual periods and interim reporting periods beginning after December 15, 2013, with early adoption permitted. The Company is evaluating the impact of this new provision on the consolidated results of operations or financial position.

In February 2013, the FASB amended its guidance to require an entity to present the effect of certain significant reclassifications out of accumulated other comprehensive income on the respective line items in net income. The new accounting guidance does not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified as net income. The guidance is effective prospectively for fiscal years beginning after December 15, 2012. The Company adopted these new provisions for the quarterly period beginning January 1, 2013. As the guidance requires additional presentation only, there was no impact on the Company's consolidated results of operations or financial position.

Restructuring

Restructuring charges are recognized as a result of actions to streamline operations and rationalize manufacturing facilities. Judgment is used when estimating the impact of restructuring plans, including future termination benefits and other exit costs to be incurred when the actions take place. Actual results could vary from these estimates.

Acquisition of Callidus Biopharma, Inc.

12 Months Ended

Dec. 31, 2013

Acquisition of Callidus Biopharma, Inc.

Acquisition of Callidus Biopharma, Inc.

3. Acquisition of Callidus Biopharma, Inc.

In November 2013, the Company acquired Callidus, through the merger of the Company's subsidiary, CB Acquisition Corp. with and into Callidus (see "— Note 1. Description of Business"). Callidus was a privately-held biologics company focused on developing best-in-class ERTs for LSDs and its lead ERT is AT-B200 for Pompe disease in late preclinical development. The acquisition of the Callidus assets and technology compliments Amicus' CHART^TM platform for the development of next generation ERTs.

In consideration for the merger, the Company agreed to issue an aggregate of 7.2 million shares of its common stock, par value $0.01 per share, to the former stockholders of Callidus. As of December 31, 2013, 4.8 million shares were issued and 2.4 million shares remain issuable to former Callidus shareholders. In addition, the Company will be obligated to make additional payments to the former stockholders of Callidus upon the achievement by Callidus of certain clinical milestones of up to $35 million and regulatory approval milestones of up to $105 million as set forth in the Merger Agreement, provided that the aggregate consideration shall not exceed $130 million. The Company may, at its election, satisfy certain milestone payments identified in the Merger Agreement aggregating $40 million in shares of its Common Stock (calculated based on a price per share equal to the average of the last closing bid price per share for the Common Stock on The NASDAQ Global Market for the ten (10) trading days immediately preceding the date of payment). The milestone payments not permitted to be satisfied in Common Stock (as well as any payments that the Company is permitted to, but chooses not to, satisfy in Common Stock), as a result of the terms of the Merger Agreement, the rules of The NASDAQ Global Market, or otherwise, will be paid in cash.

The fair value of the contingent acquisition consideration payments on the acquisition date was $10.6 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions included a discount rate of 13.5% and various probability factors. As of December 31, 2013, the range of outcomes and assumptions used to develop these estimates has not changed (see "— Note 10. Assets and Liabilities Measured at Fair Value" for additional discussion regarding fair value measurements of the contingent acquisition consideration payable).

The following table presents the allocation of the purchase consideration, including the contingent acquisition consideration payable, based on fair value:

	(in thousands)

Upfront equity payments	$	15,000
Contingent acquisition consideration payable		10,600


Total consideration	$	25,600




Cash and cash equivalents	$	34
Property, plant and equipment		173
Intangible assets — IPR&D		23,000


Total identifiable assets acquired	$	23,207


Accounts payable		(34	)
Deferred tax liability		(9,186	)


Total liabilities assumed	$	(9,220	)
Net identifiable assets acquired		13,987
Goodwill		11,613


Net assets acquired	$	25,600

A substantial portion of the assets acquired consisted of intangible assets related to Callidus lead ERT. The Company determined that the estimated acquisition-date fair values of the IPR&D related to the lead ERT was $23.0 million. The Company is still in the process of valuing the assets acquired and liabilities assumed; therefore the allocation of the acquisition consideration is still subject to change.

The $9.2 million of deferred tax liabilities relates to the tax impact of future amortization or possible impairments associated with the identified intangible assets acquired, which are not deductible for tax purposes. The goodwill results from the recognition of the deferred tax liability on the intangible assets as well as synergies expected from the acquisition and other benefits that do not qualify for separate recognition as acquired intangible assets. None of the goodwill is expected to be deductible for income tax purposes. The Company recorded the goodwill in the Company's consolidated balance sheet as of the acquisition date.

The Company recognized $0.5 million of acquisition-related transaction costs in selling, general and administrative expenses during 2013, which consisted primarily of legal fees and severance related to the acquisition.

The results of operations of Callidus since November 19, 2013 have been included in the Company's consolidated statements of operations and are de minimis as of December 31, 2013.

The following unaudited consolidated pro forma financial information presents the combined results of operations of the Company and Callidus as if the acquisition had occurred as of January 1, 2013. The unaudited pro forma consolidated financial information is not necessarily indicative of what the Company's consolidated results of operations actually would have been had the acquisition been completed as of January 1, 2013. In addition, the unaudited pro forma consolidated financial information does not attempt to project the future results of operations of the Company combined with Callidus.

	Years Ended December 31,

Unaudited Pro Forma Consolidated Information:	2012			2013
(in thousands)
Revenue	$	18,411		$	363
Net income (loss)	$	(49,807	)	$	(61,804	)

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Goodwill

12 Months Ended

Dec. 31, 2013

Goodwill

Goodwill

4. Goodwill

In connection with the acquisition of Callidus as discussed in "— Note 3. Acquisition of Callidus Biopharma, Inc.," the Company recognized goodwill of $11.6 million. Goodwill is assessed annually for impairment on October 1 and whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined that the full carrying amount of an asset is not recoverable, an impairment loss is recorded in the amount by which the carrying amount of the asset exceeds its fair value. Management determined that the carrying value did not exceed the fair value due to the short time period from the date of acquisition until the end of the year, and as a result no impairment of goodwill existed at December 31, 2013. The following table represents the changes in goodwill for the year ended December 31, 2013 (in thousands):


Balance at December 31, 2012	$	—
Goodwill related to the acquisition of Callidus (See Note 3)		11,613


Balance at December 31, 2013	$	11,613

Intangible Assets

12 Months Ended

Dec. 31, 2013

Intangible Assets

Intangible Assets

5. Intangible Assets

In connection with the acquisition of Callidus as discussed in "— Note 3. Acquisition of Callidus Biopharma, Inc.," the Company recognized IPR&D of $23.0 million. Intangible assets related to IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis on October 1 and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D assets below their respective carrying amounts. Management determined that the carrying value did not exceed the fair value due to the short time period from the date of acquisition until the end of the year and as a result, no impairment of IPR&D existed at December 31, 2013. The following table represents the changes in IPR&D for the year ended December 31, 2013 (in thousands):


Balance at December 31, 2012	$	—
IPR&D related to the acquisition of Callidus (See Note 3)		23,000


Balance at December 31, 2013	$	23,000

Cash, Money Market Funds and Marketable Securities

12 Months Ended

Dec. 31, 2013

Cash, Money Market Funds and Marketable Securities

Cash, Money Market Funds and Marketable Securities

6. Cash, Money Market Funds and Marketable Securities

As of December 31, 2013, the Company held $43.6 million in cash and cash equivalents and $38.4 million of available-for-sale securities which are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income/ (loss) in the statements of comprehensive loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other than temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. To date, only temporary impairment adjustments have been recorded.

Consistent with the Company's investment policy, the Company does not use derivative financial instruments in its investment portfolio. The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Cash and available for sale securities consisted of the following as of December 31, 2012 and December 31, 2013 (in thousands):

	As of December 31, 2012

	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	33,971	$	—	$	—		$	33,971
Corporate debt securities		42,503		5		(11	)		42,497
Commercial paper		19,725		19		—			19,744
Certificate of deposit		2,909		1		—			2,910


	$	99,108	$	25	$	(11	)	$	99,122




Included in cash and cash equivalents	$	33,971	$	—	$	—		$	33,971
Included in marketable securities		65,137		25		(11	)		65,151


Total cash and marketable securities	$	99,108	$	25	$	(11	)	$	99,122

	As of December 31, 2013

	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	43,640	$	—	$	—		$	43,640
Corporate debt securities		30,817		1		(6	)		30,812
Commercial paper		7,192		6		—			7,198
Certificate of deposit		350		—		—			350


	$	81,999	$	7	$	(6	)	$	82,000




Included in cash and cash equivalents	$	43,640	$	—	$	—		$	43,640
Included in marketable securities		38,359		7		(6	)		38,360


Total cash and marketable securities	$	81,999	$	7	$	(6	)	$	82,000

All of the Company's available for sale investments as of December 31, 2012 and December 31, 2013 are due in one year or less.

Unrealized gains and losses are reported as a component of other comprehensive gain/(loss) in the statements of comprehensive loss. For the year ended December 31, 2012 unrealized holding gains of $10 thousand and for the year ended December 31, 2013, unrealized holding loss of $13 thousand respectively, were included in the statements of comprehensive loss.

For the years ended December 31, 2012 and 2013, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.

Unrealized loss positions in the available for sale securities as of December 31, 2012 and December 31, 2013 reflect temporary impairments that have been in a loss position for less than twelve months and as such are recognized in other comprehensive gain/(loss). The fair value of these available for sale securities in unrealized loss positions was $33.1 million and $23.6 million as of December 31, 2012 and December 31, 2013, respectively.

The Company holds available-for-sale investment securities which are reported at fair value on the Company's balance sheet. Unrealized holding gains and losses are reported within accumulated other comprehensive income ("AOCI") in the statements of comprehensive loss. The changes in AOCI associated with the unrealized holding gain on available-for-sale investments during the years ended December 31, 2012 and 2013, were as follows (in thousands):

	Year Ended December 31,

	2012		2013
Balance, beginning	$	4	$	14
Current period changes in fair value,^(a)		10		(13	)
Reclassification of earnings,^(a)		—		—


Balance, ending	$	14	$	1

(a): — Taxes have not been accrued on the unrealized gain on securities as the Company is in a loss position for all periods presented

Property and Equipment

12 Months Ended

Dec. 31, 2013

Property and Equipment

Property and Equipment

7. Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,

	2012			2013
Property and equipment consist of the following:
Computer equipment	$	3,399		$	3,537
Computer software		849			1,064
Research equipment		5,807			5,918
Furniture and fixtures		1,544			1,527
Leasehold improvements		1,931			2,047


		13,530			14,093
Less accumulated depreciation and amortization		(8,501	)		(9,973	)


	$	5,029		$	4,120

Depreciation and amortization expense was $1.7 million each for the years ended December 31, 2013 and 2012 and $13.5 million for the Period February 4, 2002 (inception) to December 31, 2013, respectively. There were no capital lease obligations outstanding as of December 31, 2013.

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2013

Accounts Payable and Accrued Expenses

Accounts Payable and Accrued Expenses

8. Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,

	2012		2013
Accounts payable	$	2,115	$	2,146
Accrued professional fees		409		498
Accrued contract manufacturing & contract research costs		1,743		1,499
Accrued compensation and benefits		4,229		4,781
Accrued facility costs		167		963
Accrued other		182		275


	$	8,845	$	10,162

Stockholders' Equity

12 Months Ended

Dec. 31, 2013

Stockholders' Equity

Stockholders' Equity

9. Stockholders' Equity

Common Stock and Warrants

As of December 31, 2013, the Company was authorized to issue 125,000,000 shares of common stock. Dividends on common stock will be paid when, and if declared by the board of directors. Each holder of common stock is entitled to vote on all matters that are appropriate for shareholder voting and is entitled to one vote for each share held.

The fair value of the warrant liability issued in connection with the March 2010 registered direct offering de minimis as of December 31, 2013. These warrants expired on March 2, 2014.

In November 2013, the Company entered into the 2013 SPA with GSK and certain entities controlled by Redmile Group, LLC for the private placement of a) shares of the Company's common stock, par value $0.01 (the "Common Stock") and b) a combination of shares of Common Stock (the "Shares") and warrants (the "Warrants") to purchase shares of the Common Stock (collectively, the "Units"). Each of the investors was one of the Company's shareholders prior to consummation of these transactions. The Shares and the Units sold to the investors were offered and sold in reliance on exemptions from registration pursuant to Rule 506 of Regulation D promulgated under the Securities Act based on the nature of such investors and certain representations made to the Company. Pursuant to the 2013 SPA, Amicus agreed to issue 1.5 million Shares at $2.00 per Share to GSK and (b) 6 million Units at $2.00 per Unit to Redmile Group, with each Unit consisting of one Share and .267 Warrants resulting in an aggregate of 6 million Shares and 1.6 million Warrants underlying the Units to be issued. Each Warrant is exercisable between July 1, 2014 and June 30, 2015 with an exercise price of $2.50, subject to certain adjustments. The Company received total proceeds of $15 million for general corporate and working capital purposes as a result of the private placement and the transaction closed in November 2013. At December 31, 2013, GSK's resulting equity stake in the Company was 17.6%.

The Company evaluated the warrants against current accounting guidance and determined that these warrants should be accounted as a component of equity. As such, these warrants are valued at issuance date using the Black Scholes valuation model using inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The six inputs used to determine the value of the warrants were: (1) the closing price of Amicus stock on the day of evaluation of $2.12; (2) the exercise price of the warrants of $2.50; (3) the remaining term of the warrants of 1 year; (4) the volatility of Amicus' stock for the one year tern of 93.5%; (5) the annual rate of dividends of 0%; and (6) the riskless rate of return of 0.12%. The annual rate of dividends is based on the Company's historical practice of not granting dividends. The resulting Black Scholes value of the warrants was $1.0 million.

In November 2013, in connection with its acquisition of Callidus, the Company agreed to issue an aggregate of 7.2 million shares of its common stock, par value $0.01 per share, to the former stockholders of Callidus. As of December 31, 2013, 4.8 million of these shares were issued and balance of the shares is expected to be issued by March 31, 2014.

In July 2012, Amicus and GSK entered into the SPA pursuant to which GSK purchased 2.9 million unregistered shares of Amicus common stock at a price of $6.30 per share. The total purchase price for these shares was $18.6 million. In March 2012, the Company sold 11.5 million shares of its common stock at a public offering price of $5.70 through a Registration Statement on Form S-3 that was declared effective by the SEC in May 2009. The aggregate offering proceeds were $65.6 million.

In October 2010, GSK purchased approximately 6.9 million shares of the Company's common stock at $4.56 per share, in connection with the Original Collaboration Agreement. The total value of this equity investment was approximately $31 million.

In March 2010, the Company sold 4.95 million shares of its common stock and warrants to purchase 1.9 million shares of common stock in a registered direct offering to a selected group of institutional investors through a Registration Statement on Form S-3 that was declared effective by the SEC in May 2009. The shares of common stock and warrants were sold in units consisting of one share of common stock and one warrant to purchase 0.375 shares of common stock at a price of $3.74 per unit. The warrants have a term of four years and are exercisable any time on or after the six month anniversary of the date they were issued, at an exercise price of $4.43 per share. The aggregate offering proceeds were $18.5 million. There were approximately 1.4 million warrants outstanding at December 31, 2013. These warrants expired on March 2, 2014

Stock Option Plans

In April 2002, the Company's Board of Directors and shareholders approved the Company's 2002 Stock Option Plan (the 2002 Plan). In May 2007, the Company's Board of Directors and shareholders approved the Company's 2007 Stock Option Plan (the 2007 Plan) and 2007 Director Option Plan (the 2007 Director Plan). In June 2010, the Company's Board of Directors and shareholders approved amendments to the 2007 Plan and the 2007 Director Plan. Both the 2002 Plan and 2007 Plan provide for the granting of restricted stock and options to purchase common stock in the Company to employees, advisors and consultants at a price to be determined by the Company's board of directors. The 2002 Plan and the 2007 Plan are intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The Options may be incentive stock options (ISOs) or non-statutory stock options (NSOs). Under the provisions of each plan, no option will have a term in excess of 10 years. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The options granted under the 2007 Director Plan are NSOs and under the provisions of this plan, no option will have a term in excess of 10 years.

The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. Options granted pursuant to both the 2002 Plan and the 2007 Plan generally vest 25% on the first year anniversary date of grant plus an additional 1/48th for each month thereafter and may be exercised in whole or in part for 100% of the shares vested at any time after the date of grant. Options under the 2007 Director Plan may be granted to new directors upon joining the Board and vest in the same manner as options under the 2002 and 2007 Plans. In addition, options are automatically granted to all directors at each annual meeting of stockholders and vest on the date of the annual meeting of stockholders of the Company in the year following the year during which the options were granted.

As of December 31, 2013, there were no shares reserved for issuance under the 2002 Plan. The Company has reserved up to 2,508,411 shares for issuance under the 2007 Plan and the 2007 Director Plan.

The Company recognized stock-based compensation expense of $8.7 million, $6.2 million and $6.2 million in 2011, 2012 and 2013, respectively. The following table summarizes the stock compensation expense recognized in the statements of operations (in thousands):

	Years Ended December 31,

	2011		2012		2013
Stock compensation expense recognized in:
Research and development expense	$	2,928	$	3,603	$	3,583
General and administrative expense		5,751		2,588		2,594


Total stock compensation expense	$	8,679	$	6,191	$	6,177

The Company adopted the fair value method of measuring stock-based compensation, which requires a public entity to measure the cost of employee services received in exchange for an award of equity instruments based upon the grant-date fair value of the award. The Company chose the "straight-line" attribution method for allocating compensation costs and recognized the fair value of each stock option on a straight-line basis over the vesting period of the related awards.

The Company uses the Black-Scholes option pricing model when estimating the fair value for stock-based awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility was calculated based on a blended weighted average of historical information of the Company's stock and the weighted average of historical information of similar public entities for which historical information was available. The Company will continue to use a blended weighted average approach using its own historical volatility and other similar public entity volatility information until the Company's historical volatility is relevant to measure expected volatility for future option grants. The average expected life was determined using the "simplified" method of estimating the expected exercise term which is the mid-point between the vesting date and the end of the contractual term. As the Company's stock price volatility has been over 75% and it has experienced significant business transactions (Shire and GSK collaborations), the Company does not have sufficient reliable exercise data in order to justify a change in the use of the "simplified" method of estimating the expected exercise term of employee stock option grants. The risk-free interest rate is based on U.S. Treasury, zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. Forfeitures are estimated based on voluntary termination behavior, as well as a historical analysis of actual option forfeitures.

The weighted average assumptions used in the Black-Scholes option pricing model are as follows:

	Years Ended December 31,

	2011			2012			2013
Expected stock price volatility		78.8	%		77.2	%		82.0	%
Risk free interest rate		2.0	%		0.8	%		1.3	%
Expected life of options (years)		6.25			6.25			6.25
Expected annual dividend per share	$	0.00		$	0.00		$	0.00

The weighted-average grant-date fair value per share of options granted during 2011, 2012 and 2013 were $4.11, $3.31 and $2.14, respectively.

The following table summarizes information about stock options outstanding:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

	(in thousands)						(in thousands)
Options outstanding, December 31, 2010		5,104.1		$	7.27
Granted		2,217.0		$	5.92
Exercised		(108.5	)	$	3.88
Forfeited		(559.1	)	$	7.34


Options outstanding, December 31, 2011		6,653.5		$	6.87
Granted		2,846.6		$	5.34
Exercised		(437.0	)	$	3.73
Forfeited		(1,088.9	)	$	7.95


Options outstanding, December 31, 2012		7,974.2		$	6.35
Granted		2,481.8		$	3.04
Exercised		—			—
Forfeited		(1,414.9	)	$	5.01


Options outstanding, December 31, 2013		9,041.1		$	5.65	7.0 years	$	44.4




Vested and unvested expected to vest, December 31, 2013		8,637.7		$	5.73	6.9 years	$	43.3
Exercisable at December 31, 2013		5,502.7		$	6.68	5.8 years	$	38.5

The aggregate intrinsic value of options exercised during the years ended December 31, 2011 and 2012 was $0.3 million and $0.9 million, respectively. There were no options exercised during the year ended December 31, 2013. As of December 31, 2013, the total unrecognized compensation cost related to non-vested stock options granted was $7.3 million and is expected to be recognized over a weighted average period of 2.3 years. Cash proceeds from stock options exercised during the years ended December 31, 2011 and 2012 were $0.4 million and $1.6 million respectively.

Restricted Stock Awards — Restricted stock awards are granted subject to certain restrictions, including in some cases service conditions (restricted stock). The grant-date fair value of restricted stock awards, which has been determined based upon the market value of the Company's shares on the grant date, is expensed over the vesting period.

Upon vesting in 2011, there were 13,225 shares surrendered to fund minimum statutory tax withholding requirements. There were no restricted stock awards in 2011, 2012 or 2013. As of December 31, 2013, there was no unrecognized compensation cost related to unvested restricted stock awards. The total fair value of restricted stock awards which vested during 2011 was $0.4 million.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Assets and Liabilities Measured at Fair Value

12 Months Ended

Dec. 31, 2013

Assets and Liabilities Measured at Fair Value

Assets and Liabilities Measured at Fair Value

10. Assets and Liabilities Measured at Fair Value

The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy which is defined as follows:

- Level 1 — Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
  
  Level 2 — Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.
  
  Level 3 — Inputs that are unobservable for the asset or liability.
Cash, Money Market Funds and Marketable Securities

The Company classifies its cash and money market funds within the fair value hierarchy as Level 1 as these assets are valued using quoted prices in active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available for sale and classifies these assets within the fair value hierarchy as Level 2 primarily utilizing broker quotes in a non-active market for valuation of these securities. No changes in valuation techniques or inputs occurred during the year ended December 31, 2013. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the year ended December 31, 2013.

Secured Debt

As disclosed in Note 16, the Company has a new loan and security agreement with MidCap Financial, Oxford Finance and Silicon Valley Bank, in addition to an earlier existing loan with Silicon Valley Bank. The carrying amount of the Company's borrowings approximates fair value at December 31, 2013. The Company's secured debt is classified as Level 2 and the fair value is estimated using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals.

In connection with the Term Loan, as disclosed in Note 16, the Company recorded a contingent liability of approximately $0.3 million representing the fair value of a contingent payment of up to $0.4 million related to a success fee payable within six months of trigger event, with the trigger event being regulatory acceptance of NDA or MMA submission. This is effective 5 years from the closing of the Term Loan. The success fee payable to the lender was probability adjusted and discounted utilizing an appropriate discount rate and hence classified as Level 3.

Contingent Consideration Payable

The Contingent consideration payable arises from acquisition of Callidus, as discussed in Note 3. The valuation of the contingent consideration payable is estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the contingent consideration payable will be recorded in intangible asset amortization and contingent consideration in the Company's consolidated statements of operations.

Warrants

The Company allocated $3.3 million of proceeds from its March 2010 registered direct offering to warrants issued in connection with the offering that was classified as a liability. The valuation of the warrants is determined using the Black-Scholes model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the warrant liability should be classified within Level 3 of the fair value hierarchy by evaluating each input for the Black-Scholes model against the fair value hierarchy criteria and using the lowest level of input as the basis for the fair value classification. There are six inputs: closing price of Amicus stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of Amicus' stock over that term; annual rate of dividends; and the riskless rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrant agreements. The annual rate of dividends is based on the Company's historical practice of not granting dividends. The closing price of Amicus stock would fall under Level 1 of the fair value hierarchy as it is a quoted price in an active market. The riskless rate of return is a Level 2 input, while the historical volatility is a Level 3 input in accordance with the fair value accounting guidance. Since the lowest level input is a Level 3, the Company determined the warrant liability is most appropriately classified within Level 3 of the fair value hierarchy. This liability is subject to fair value mark-to-market adjustment each period. The Company recognized the change in the fair value of the warrant liability as non-operating income of $0.9 million for the year ended December 31, 2013. There was no resulting fair value of the warrant liability at December 31, 2013. The weighted average assumptions used in the Black-Scholes valuation model for the warrants are as follows:

	December 31,

	2012			2013
Expected stock price volatility		93.2	%		45.9	%
Risk free interest rate		0.17	%		0.07	%
Expected life of warrants (years)		1.17			0.17
Expected annual dividend per share	$	0.00		$	0.00

A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2012 are identified in the following table (in thousands):

	Level 1		Level 2		Total

*Assets:*
Cash/money market funds	$	33,971	$	—	$	33,971
Commercial paper		—		19,744		19,744
Corporate debt securities		—		42,497		42,497
Certificate of deposit		—		2,910		2,910


	$	33,971	$	65,151	$	99,122

	Level 1		Level 2		Level 3		Total

*Liabilities:*
Secured debt	$	—	$	697	$	—	$	697
Warrant liability		—		—		908		908


	$	—	$	697	$	908	$	1,605

A summary of the fair value of the Company's assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2013 are identified in the following table (in thousands):

	Level 1		Level 2		Total

*Assets:*
Cash/money market funds	$	43,640	$	—	$	43,640
Commercial paper		—		7,198		7,198
Corporate debt securities		—		30,812		30,812
Certificate of deposit		—		350		350


	$	43,640	$	38,360	$	82,000

	Level 1		Level 2		Level 3		Total

*Liabilities:*
Secured debt	$	—	$	14,473	$	—	$	14,473
Contingent success fee payable		—		—		264		264
Warrant liability		—		—		—		—
Contingent consideration payable		—		—		10,600		10,600


	$	—	$	14,473	$	10,864	$	25,337

The change in the fair value of the Level 3 liability was a decrease of $0.7 million at December 31, 2012, after settlement of $0.3 million upon the exercise of 0.5 million warrants. The change in the fair value of Level 3 liabilities at December 31, 2013 was an increase of $10.0 million due to the addition of the contingent consideration payable of $10.6 million and contingent success fee payable of $0.3 million, offset by the decrease in the fair value of the warrant liability of $0.9 million.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2013
401(k) Plan
401(k) Plan	11. 401(k) Plan The Company has a 401(k) plan (the Plan) covering all eligible employees. During 2007, the Board of Directors approved a company matching program that began on January 1, 2008. The matching program allows for a company match of up to 5% of salary and bonus paid during the year. In 2013, the Company changed the vesting policy whereby the match vests immediately upon enrollment. The Company's total contribution to the Plan was $0.6 million, $0.7 million and $0.7 million for the years ended December 31, 2011, 2012 and 2013, respectively.

Leases

12 Months Ended

Dec. 31, 2013

Leases

Leases

12. Leases

Operating Leases

In 2011, the Company entered into a lease agreement to lease approximately 73,646 square feet of laboratory and office space in Cranbury, New Jersey. The initial term of the lease, which commenced in March 2012, is for seven years and may be extended by the Company for two additional five-year periods. In 2008, the Company entered into a lease agreement for its laboratory and office space in San Diego, CA, which will expire in September 2016. As part of the restructuring efforts, this location was closed as of December 31, 2013, however lease payments will continue to be made until end of lease term. See Note 17- Restructuring Charges for more information. Rent expenses for the Company's facilities are recognized over the term of the lease. The Company recognizes rent starting when possession of the facility is taken from the landlord. When a lease contains a predetermined fixed escalation of the minimum rent, the Company recognizes the related rent expense on a straight-line basis and records the difference between the recognized rental expense and the amounts payable under the lease as deferred rent liability. Tenant leasehold improvement allowances are reflected in accrued expenses on the consolidated balance sheets and are amortized as a reduction to rent expense in the statement of operations over the term of the lease.

At December 31, 2013, aggregate annual future minimum lease payments under these leases are as follows (in thousands):



Operating Leases
Years ending December 31:
2014	$	1,930
2015		2,033
2016		2,039
2017		1,769
2018 and beyond		2,074


	$	9,845

Rent expense for the years ended December 31, 2011, 2012 and 2013 were $2.3 million, $2.6 million and $2.6 million respectively.

Income Taxes

12 Months Ended

Dec. 31, 2013

Income Taxes

Income Taxes

13. Income Taxes

In June 2006, the FASB issued a single model to address accounting for uncertainty in tax positions. The model clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. It also provides guidance on de-recognition, measurement, and classification of amounts relating to uncertain tax positions, accounting for and disclosure of interest and penalties, accounting in interim periods and disclosures required. The Company adopted the FASB requirements as of January 1, 2007 and determined that it did not have a material impact on the Company's financial position and results of operations. The Company did not recognize interest or penalties related to income tax during the period ended December 31, 2013 and did not accrue for interest or penalties as of December 31, 2013. The Company does not have an accrual for uncertain tax positions as of December 31, 2013. Tax returns for all years 2006 and thereafter are subject to future examination by tax authorities.

Deferred income taxes reflect the net effect of temporary difference between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The significant components of the deferred tax assets and liabilities are as follows (in thousands):

	For Years Ended December 31,

	2012			2013
Current deferred tax asset
Non-cash stock issue	$	7,100		$	8,172
Others		1,257			1,343


		8,357			9,515
Non-current deferred tax assets
Amortization/depreciation		3,176			3,068
Research tax credit		9,072			13,680
Net operating loss carry forwards		62,060			79,984
Deferred revenue		12,149			14,649
Others		520			682


Gross deferred tax assets		95,334			121,578
Deferred tax liability related to business acquisition		—			(9,186	)


Total net deferred tax asset		95,334			112,392
Less valuation allowance		(95,334	)		(121,578	)


Net deferred tax assets (liability)	$	—		$	(9,186	)

The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2012, and 2013, the Company recorded valuation allowances of $95.3 million and $121.6 million, respectively, representing an increase in the valuation allowance of $20.1 million in 2012 and an increase of $26.3 million in 2013, due to the uncertainty regarding the realization of such deferred tax assets, to offset the benefits of net operating losses generated during those years.

As of December 31, 2013, the Company had federal and state net operating loss carry forwards (NOLs) of approximately $203.8 million and $179.9 million, respectively. The federal carry forward will expire in 2028 through 2032. Most of the state carry forwards generated prior to 2009 began to expire in 2012 and will continue to expire through 2015. The remaining state carry forwards including those generated in 2009 through 2012 will expire in 2029 through 2032 due to a change in the New Jersey state law regarding the net operating loss carry forward period. Utilization of NOLs may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOLs that can be utilized annually to offset future taxable income and tax, and may, in turn, result in the expiration of a portion of those carry forwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. The Company completed a detailed study of its NOLs and determined that in 2013, there was no ownership change in excess of 50%; therefore there was no write-down to net realizable value of the federal NOLs and research and development credits subject to the 382 limitations. A tax benefit of $2.0 million associated with the exercise of stock options will be recorded in additional paid-in capital when the associated net operating loss is recognized.

A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2011, 2012 and 2013 are as follows:

	Years Ended December 31,

	2011			2012			2013
Statutory rate		(34	)%		(34	)%		(34	)%
State taxes, net of federal benefit		(13	)		(3	)		(5	)
Permanent adjustments		3			—			(1	)
R&D credit		—			(8	)		(3	)
Other		2			1			—
Valuation allowance		34			38			37


Net		(8	)%		(6	)%		(6	)%

The Company recognized a tax benefit of $3.6 million, $3.2 million and $3.5 million in connection with the sale of net operating losses and research and development credits in the New Jersey Transfer Program for the years ended December 31, 2011, 2012 and 2013, respectively.

Licenses	12 Months Ended
Licenses	Dec. 31, 2013
Licenses
Licenses	14. Licenses The Company acquired rights to develop and commercialize its product candidates through licenses granted by various parties. The following summarizes the Company's material rights and obligations under those licenses: Mt. Sinai School of Medicine of New York University (MSSM) — The Company acquired exclusive worldwide patent rights to develop and commercialize migalastat HCl, afegostat and AT2220 and other pharmacological chaperones for the prevention or treatment of human diseases or clinical conditions by increasing the activity of wild-type and mutant enzymes pursuant to a license agreement with MSSM. In connection with this agreement, the Company issued 232,266 shares of common stock to MSSM in April 2002. In 2006, the Company amended its license agreement with MSSM to expand its exclusive worldwide patent rights to develop and commercialize pharmacological chaperones. In connection with the amendment, the Company paid $1.0 million and issued 133,333 shares of its common stock with an estimated fair value of $1.2 million to MSSM. In total, the Company recorded $2.2 million of research and development expense in connection with the amendment in 2006. This agreement expires upon expiration of the last of the licensed patent rights, which will be in 2019, subject to any patent term extension that may be granted, or 2024 if the Company develops a product for combination therapy (pharmacological chaperone plus ERT) and a patent issues from the pending application covering combination therapy, subject to any patent term extension that may be granted. Under this agreement, to date the Company has paid no upfront or annual license fees and has no milestone or future payments other than royalties on net sales. In 2008, the Company amended and restated its license agreement with MSSM which consolidated previous amendments into a single agreement, clarified the portion of royalties and milestone payments the Company received from collaboration agreements that were payable to MSSM, and provided the Company with the sole right to control the prosecution of patent rights described in the amended and restated license agreement. For further information see "— Note 15. Collaborative Agreements." Under the terms of the amended and restated license agreement, the Company agreed to pay $2.6 million to MSSM in connection with the $50 million upfront payment that the Company received from a collaboration agreement in November 2007 and an additional $2.6 million for the sole right to and control over the prosecution of patent rights. In accordance with the Company's license agreement with MSSM, the Company paid $3 million of the $30 million upfront payment received from GSK to MSSM in December 2010 and $0.35 million of the $3.5 million milestone payment received from GSK in August 2012, pursuant to the Original Collaboration Agreement. These payments to MSSM are classified as research and development expenses in the Company's financial statements. University of Maryland, Baltimore County — The Company acquired exclusive U.S. patent rights to develop and commercialize afegostat for the treatment of Gaucher disease from the University of Maryland, Baltimore County. Under this agreement, the Company paid upfront and annual license fees of $45 thousand, which were expensed as research and development expense. The Company is required to make a milestone payment upon the demonstration of safety and efficacy of afegostat for the treatment of Gaucher disease in a Phase 2 study, and another payment upon receiving FDA approval for afegostat for the treatment of Gaucher disease. Upon satisfaction of both milestones, the Company could be required to make up to $0.2 million in aggregate payments. The Company is also required to pay royalties on net sales. This agreement expires upon expiration of the last of the licensed patent rights in 2015. Novo Nordisk A/S — The Company acquired exclusive patent rights to develop and commercialize afegostat for all human indications. Under this agreement, to date the Company paid $0.4 million in license fees which were expensed as research and development expense. The Company is also required to make milestone payments based on clinical progress of afegostat, with a payment due after initiation of a Phase 3 clinical trial for afegostat for the treatment of Gaucher disease, and a payment due upon each filing for regulatory approval of afegostat for the treatment of Gaucher disease in any of the US, Europe or Japan. An additional payment is due upon approval of afegostat for the treatment of Gaucher disease in the U.S. and a payment is also due upon each approval of afegostat for the treatment of Gaucher disease in either Europe or Japan. Assuming successful development of afegostat for the treatment of Gaucher disease in the U.S., Europe and Japan, total milestone payments would be $7.8 million. The Company is also required to pay royalties on net sales. This license will terminate in 2016. Under its license agreements, if the Company owes royalties on net sales for one of its products to more than one of the above licensors, then it has the right to reduce the royalties owed to one licensor for royalties paid to another. The amount of royalties to be offset is generally limited in each license and can vary under each agreement. For migalastat HCl and AT2220, the Company will owe royalties only to MSSM and will owe no milestone payments. The Company would expect to pay royalties to all three licensors with respect to afegostat tartrate should the Company advance it to commercialization. The Company's rights with respect to these agreements to develop and commercialize migalastat HCl, afegostat and AT2220 may terminate, in whole or in part, if the Company fails to meet certain development or commercialization requirements or if the Company does not meet its obligations to make royalty payments.

Collaborative Agreements	12 Months Ended
Collaborative Agreements	Dec. 31, 2013
Collaborative Agreements
Collaborative Agreements	15. Collaborative Agreements GSK In October 2010, the Company entered into the Original Collaboration Agreement with Glaxo Group Limited, an affiliate of GSK, to develop and commercialize migalastat HCl. Under the terms of the Original Collaboration Agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. In consideration of the license grant, the Company received an upfront, license payment of $30 million from GSK and was eligible to receive further payments of approximately $173.5 million upon the successful achievement of development, regulatory and commercialization milestones, as well as tiered double-digit royalties on global sales of migalastat HCl. Potential payments included up to (i) $13.5 million related to the attainment of certain clinical development objectives and the acceptance of regulatory filings in select worldwide markets, (ii) $80 million related to market approvals for migalastat HCl in selected territories throughout the world, and (iii) $80 million associated with the achievement of certain sales thresholds. GSK and the Company were jointly funding development costs in accordance with an agreed upon development plan. Additionally, GSK purchased approximately 6.9 million shares of the Company's common stock at $4.56 per share, a 30% premium on the average price per share of the Company's stock over a 60 day period preceding the closing date of the transaction. The total value of this equity investment to the Company was approximately $31 million. In July 2012, the Company entered into the Expanded Collaboration Agreement with GSK pursuant to which the Company and GSK continue to develop and commercialize migalastat HCl, currently in Phase 3 development for the treatment of Fabry disease. The Expanded Collaboration Agreement amended and replaced in its entirety the Original Collaboration Agreement. Under the terms of the Expanded Collaboration Agreement, the Company and GSK were to co-develop all formulations of migalastat HCl for Fabry disease, including the development of migalastat HCl co-formulated with an investigational enzyme replacement therapy (ERT) for Fabry disease (the "Co-formulated Product"). Additionally, simultaneous with entry into the Expanded Collaboration Agreement, Amicus and GSK entered into an SPA pursuant to which GSK purchased approximately 2.9 million shares of Amicus common stock at a price of $6.30 per share for proceeds of $18.6 million. In November 2013, Amicus entered into the Revised Agreement with GSK, pursuant to which Amicus has obtained global rights to develop and commercialize migalastat HCl as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the Expanded Agreement entered into between Amicus and GSK in July 2012. Under the terms of the Revised Agreement, there was no upfront payment from Amicus to GSK. For the next-generation Fabry ERT (migalastat HCl co-formulated with ERT), GSK is eligible to receive single-digit royalties on net sales in eight major markets outside the U.S. For migalastat HCl monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. Under the terms of the Revised Agreement, GSK will no longer jointly fund development costs for all formulations of migalastat HCl. Under the Original Collaboration Agreement, the upfront license fee, together with the premium received on the stock purchase, was being recognized as Collaboration Revenue over the original development period. In addition, the Company was receiving reimbursements of research expenditures under the cost sharing arrangement which was being accounted for as Research Revenue on the statement of operations. Under the Expanded Collaboration Agreement, the Company will continue to receive research expense reimbursements for the development of migalastat HCl but may be required to pay contingent milestones to GSK in the future related to the U.S. commercial rights to migalastat HCl. In accordance with the revenue recognition guidance related to multiple-element arrangements, the Company identified all of the deliverables at the inception of the Expanded Collaboration Agreement. The significant deliverables were determined to be the rest of world licensing rights to migalastat HCl, the research services to continue and complete the development of migalastat HCl and the delivery of the Company's common stock. The Company determined that the rest of world licensing rights and the research services represent one unit of accounting as none of these deliverables on its own has standalone value separate from the other. The Company also determined that the delivery of the Company's common stock does have standalone value separate from the rest of world licensing rights and the research services. As a result, the Company's common stock was considered a separate unit of accounting and was accounted for as an issuance of common stock. However, as the Company's common stock was sold at a premium to the market closing price, the premium amount paid over the market closing price was determined to be additional consideration paid to the Company for the collaboration agreement and was included as consideration for the single unit of accounting (rest of world licensing rights and research services) identified above. In evaluating the impact of both the Expanded Collaboration Agreement and the Revised Agreement, the Company applied the accounting guidance regarding the impact of potential future payments it may make in its role as a vendor (i.e., Amicus) to its customer (GSK) and evaluated if these potential future payments could be a reduction of revenue from GSK. If the potential future payments to GSK are as follows: • a payment for an identifiable benefit, and • the identifiable benefit is separable from the existing relationship between the Company and GSK, and • the identifiable benefit can be obtained from a party other than GSK, and • the Company can reasonably estimate the fair value of the identifiable benefit, then the potential future payments would be treated separately from the collaboration and research revenue. However, if all these criteria are not satisfied, then the potential future payments are treated as a reduction of revenue. Accordingly, the Company does not believe that, for accounting purposes, the new U.S. licensing rights to migalastat HCl obtained from GSK under the Expanded Collaboration Agreement, nor the ex U.S. licensing rights to migalastat HCl obtained from GSK under the Revised Agreement, represent a separate, identifiable benefit from the licenses in the Original Collaboration Agreement. The contingent amounts payable to GSK are not sufficiently separable from GSK's original license and the research and development reimbursements such that Amicus could not have entered into a similar exchange transaction with another party. Additionally, the Company cannot reasonably estimate the fair value of the worldwide licensing rights to migalastat HCl. The Company determined that the potential future payments to GSK would be treated as a reduction of revenue and that the total amount of revenue to be received under the arrangement is no longer fixed or determinable as the contingent milestone payments are subject to significant uncertainty. As a result, the Company no longer recognizes any of the upfront license fees and premiums on the equity purchase from GSK until such time as the arrangement consideration becomes fixed or determinable, because an indeterminable amount may ultimately be payable back to GSK. These amounts (the balance of the unrecognized upfront license fee and the premium on the equity purchases) are classified as deferred reimbursements on the balance sheet. The recognition of Research Revenue is also affected by the determination that the overall total arrangement consideration is no longer fixed and determinable, despite the fact that the research activities will continue and that the research expense reimbursements by GSK to Amicus will be received as the research activities related to the reimbursement would have already been completed. Therefore any research reimbursements from GSK are recorded as deferred reimbursements on the balance sheet and not recognized until the total arrangement consideration becomes fixed and determinable. As a result, all revenue recognition was suspended until the total arrangement consideration becomes fixed and determinable. In addition, future milestone payments made by the Company will be applied against the balance of this deferred reimbursements account. In the third quarter of 2013, the Company paid GSK a pass-through milestone payment of $0.8 million in connection with the development of the Co-formulated product. This payment is reflected as a reduction of the deferred reimbursements in the Consolidated Balance Sheet as of December 31, 2013. Revenue recognition for research expense reimbursements, the original upfront license fee, and the equity premiums will resume once the total arrangement consideration becomes fixed and determinable which will occur when the balance of the deferred reimbursements account is sufficient to cover all the remaining contingent milestone payments. Under the Original Collaboration Agreement, the Company evaluated the contingent milestones and determined that they were substantive milestones and would be recognized as revenue in the period that the milestone is achieved. The Company determined that the research based milestones were commensurate with the enhanced value of each delivered item as a result of the Company's specific performance to achieve the milestones. The research based milestones would have related to past performances when achieved and were reasonable relative to the other payment terms within the Original Collaboration Agreement. In June 2012, the Company achieved a clinical development milestone and recognized $3.5 million of milestone revenue. Under the terms of the Expanded Collaboration Agreement, the Company is no longer entitled to receive any milestone payments from GSK. Biogen In September 2013, the Company entered into a license and collaboration agreement (the "Biogen Agreement") with Biogen to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. Under terms of the multi-year agreement, the Company and Biogen will collaborate in the discovery of a new class of small molecules that target the GCase enzyme, for further development and commercialization by Biogen. Biogen will be responsible for funding all discovery, development, and commercialization activities. In addition the Company will be reimbursed for all full-time employees working on the project as part of a cost sharing arrangement. The Company is also eligible to receive development and regulatory milestones, as well as modest royalties in global net sales. In accordance with the revenue recognition guidance related to reimbursement of research and development expenses, the Company identified all deliverables at the inception of the agreement. The Company has not commenced its planned principal operations (i.e. selling commercial products) and is therefore a development stage enterprise. The Company is only performing development of its compounds, and therefore, development activities are part of the Company's ongoing central operations. Additionally, the Company has the following accounting policies: • Research and development expenses related to a collaboration agreement will be recorded on a gross basis in the income statement and not presented net of any reimbursement received from a collaboration agreement; and • The reimbursement of research and development expenses from a collaborator will be recognized in the income statement as "Research Revenue" for the period in which the research activity occurred. As of December 31, 2013, the Company recognized $0.4 million in Research Revenue for work performed under the cost sharing arrangement of the Biogen Agreement. The Company evaluated the contingent milestones included in the Biogen Agreement at the inception of the Biogen Agreement and determined that the contingent milestones are substantive milestones and will be recognized as revenue in the period that the milestone is achieved. The Company determined that the research based milestones are commensurate with the enhanced value of each delivered item as a result of the Company's specific performance to achieve the milestones. The research based milestones would relate to past performances when achieved and are reasonable relative to the other payment terms within the Biogen Agreement, including the cost sharing arrangement.

Short-Term Borrowings and Long-Term Debt

12 Months Ended

Dec. 31, 2013

Short-Term Borrowings and Long-Term Debt

Short-Term Borrowings and Long-Term Debt

16. Short-Term Borrowings and Long-Term Debt

In August 2011, the Company entered into a loan and security agreement (the "2011 Loan Agreement") with Silicon Valley Bank ("SVB") in order to finance certain capital expenditures to be made by the Company in connection with its move in March 2012 to new office and laboratory space in Cranbury, New Jersey. The 2011 Loan Agreement provided for up to $3 million of equipment financing through January 2014. Borrowings under the 2011 Loan Agreement were collateralized by equipment purchased with the proceeds of the loan and bear interest at a variable rate of SVB prime + 2.5%. The current SVB prime rate is 4.0%. In February 2012, the Company borrowed approximately $1.0 million from the 2011 Loan Agreement which will be repaid over the following 2.5 years. The 2011 Loan Agreement contains financial covenants and the Company has at all times been in compliance with these covenants. At December 31, 2013, the total amount due under the 2011 Loan Agreement was $0.3 million.

In December 2013, the Company entered into a credit and security agreement (the "Agreement") with a lending syndicate consisting of MidCap Funding III, LLC, Oxford Finance LLC, and Silicon Valley Bank which provides an aggregate of $25 million (the "Term Loan"). The Company drew $15 million of the aggregate principal amount of the Term Loan at the end of December 2013 (the "First Tranche") and may draw up to an additional $10 million through the end of the fourth quarter of 2014 (the "Second Tranche"). The principal outstanding balance of the First Tranche bears interest at a rate per annum fixed at 8.5%. If the Company draws from the Second Tranche, the principal outstanding balance of the Second Tranche will also have a fixed interest rate, which will be determined by reference to the applicable index rate at the time of the draw. The Company will make interest-only payments on the Term Loan beginning January 1, 2014 and continuing through April 1, 2015, after which the Company will repay the aggregate principal outstanding balance of the Term Loan in 33 equal monthly installments of principal, plus accrued interest at the applicable rate. The Term Loan matures on December 27, 2017. At December 31, 2013, the total principal amount due under the Term Loan was $15 million.

In connection with the Term Loan, the Company recorded a debt discount of $0.8 million at December 31, 2013 which consists of payments to be made and a contingent payable to the lenders. These payments include a debt facility fee of $0.1 million which was paid on the date of the First Tranche, $0.4 million exit fee that will be payable upon repayment of the term loan and $0.3 million representing the fair value of a contingent payment of up to $0.4 million related to a success fee payable within six months of trigger event, with the trigger event being regulatory acceptance of NDA or MMA submission. This is effective 5 years from the closing of the Term Loan. The success fee payable to the lender was probability adjusted and discounted utilizing an appropriate discount rate and is shown as a non-current liability on the Company's consolidated balance sheet.

The carrying amount of the Company's borrowings approximates fair value at December 31, 2013.

The remaining future minimum payments of principal due as of December 31, 2013 are as follows (in thousands):


Years ending December 31:
2014	$	299
2015		4,035
2016		5,443
2017		5,522
2018 and beyond		—


Total principal obligation		15,299
Less short-term portion		(299	)


Long-term portion, gross of debt discount		15,000
Less debt discount		(826	)


Long term portion, net of debt discount	$	14,174

Restructuring Charges

12 Months Ended

Dec. 31, 2013

Restructuring Charges

Restructuring Charges

17. Restructuring Charges

In November 2013, the Company announced a work-force reduction of approximately 14 percent, or 15 employees, as a part of a corporate restructuring. This measure was intended to reduce costs and to align the Company's resources with its key strategic priorities.

In December 2013, the Company initiated and completed a facilities consolidation effort, closing one of its subleased locations in San Diego, CA. The Company recorded a total charge of $1.9 million during the fourth quarter of 2013 which included $1.2 million for employment termination costs payable and a facilities consolidation charge of $0.8 million consisting of lease payments of $0.7 million related to the net present value of the net future minimum lease payments at the cease-use date and the write-down of the net book value of fixed assets in the vacated building of $0.1 million. At December 31, 2013, $1.1 million of the restructuring charges related to employment termination costs were unpaid and classified under accrued expenses on the balance sheet.

The following table summarizes the restructuring charges and utilization for the year ended December 31, 2013 (in thousands):

	Balance as of December 31, 2012		Charges		Cash Payments			Adjustments		Balance as of December 31, 2013

Employment termination costs	$	—	$	1,227	$	(88	)	$	—	$	1,139
Facilities consolidation		—		703		—			—		703
Property and equipment disposal		—		58		—			—		—


Total	$	—	$	1,988	$	(88	)	$	—	$	1,842

Employment termination costs will be paid within one year and the lease charges will be paid over the remaining lease term which expires in September 2016.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2013
Subsequent Events
Subsequent Events	18. Subsequent Events The Company evaluated events that occurred subsequent to December 31, 2013 and there were no material recognized or non-recognized subsequent events during this period.

Selected Quarterly Financial Data (Unaudited - in thousands except per share data)

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Data (Unaudited - in thousands except per share data)

Selected Quarterly Financial Data (Unaudited - in thousands except per share data)

19. Selected Quarterly Financial Data (Unaudited — in thousands except per share data)

	Quarters Ended

	March 31			June 30			September 30			December 31
2012
Net loss		(13,137	)		(9,343	)		(16,290	)		(10,015	)
Basic and diluted net loss per common share ⁽¹⁾		(0.35	)		(0.20	)		(0.34	)		(0.20	)
2013
Net loss		(17,458	)		(15,349	)		(14,589	)		(12,237	)
Basic and diluted net loss per common share ⁽¹⁾		(0.35	)		(0.31	)		(0.29	)		(0.22	)

(1): Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies

Basis of Presentation

Basis of Presentation

Consolidation

Consolidation

Use of Estimates

Use of Estimates

Cash, Money Market Funds, and Marketable Securities

Cash, Money Market Funds, and Marketable Securities

The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition, to be cash equivalents.

Concentration of Credit Risk

Concentration of Credit Risk

Property and Equipment

Property and Equipment

Revenue Recognition

Revenue Recognition

•

a payment for an identifiable benefit; and

•

the identifiable benefit is separable from the existing relationship between the Company and its customer; and

•

the identifiable benefit can be obtained from a party other than the customer; and

•

the Company can reasonably estimate the fair value of the identifiable benefit

Fair Value Measurements

Fair Value Measurements

Research and Development Costs

Research and Development Costs

Interest Income and Interest Expense

Interest Income and Interest Expense

Interest income consists of interest earned on the Company's cash and cash equivalents and marketable securities. Interest expense consists of interest incurred on capital leases and secured debt.

Other Income and Expenses

Other Income and Expenses

Income Taxes

Income Taxes

Other Comprehensive Income/ (Loss)

Other Comprehensive Income/ (Loss)

Components of other comprehensive income/ (loss) include unrealized gains and losses on available-for-sale securities and are included in the statements of comprehensive loss.

Leases

Leases

Stock-Based Compensation

Stock-Based Compensation

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

Basic and Diluted Net Loss Attributable to Common Stockholders per Common Share

	Years Ended December 31,

	2011			2012			2013
Historical
Numerator:
Net loss attributable to common stockholders	$	(44,412	)	$	(48,785	)	$	(59,633	)




Denominator:
Weighted average common shares outstanding — basic and diluted		34,569,642			45,565,217			51,286,059

Dividends

Dividends

Segment Information

Segment Information

Business Combinations

Business Combinations

Contingent Consideration Payable

Contingent Consideration Payable

Intangible Assets and Goodwill

Intangible Assets and Goodwill

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Restructuring

Restructuring

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2013

Summary of Significant Accounting Policies

Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share

	Years Ended December 31,

	2011			2012			2013
Historical
Numerator:
Net loss attributable to common stockholders	$	(44,412	)	$	(48,785	)	$	(59,633	)




Denominator:
Weighted average common shares outstanding — basic and diluted		34,569,642			45,565,217			51,286,059

Acquisition of Callidus Biopharma, Inc. (Tables)

12 Months Ended

Dec. 31, 2013

Acquisition of Callidus Biopharma, Inc.

Schedule of allocation of purchase consideration, including the contingent acquisition consideration payable, based on fair value

	(in thousands)

Upfront equity payments	$	15,000
Contingent acquisition consideration payable		10,600


Total consideration	$	25,600




Cash and cash equivalents	$	34
Property, plant and equipment		173
Intangible assets — IPR&D		23,000


Total identifiable assets acquired	$	23,207


Accounts payable		(34	)
Deferred tax liability		(9,186	)


Total liabilities assumed	$	(9,220	)
Net identifiable assets acquired		13,987
Goodwill		11,613


Net assets acquired	$	25,600

Schedule of unaudited consolidated pro forma financial information

	Years Ended December 31,

Unaudited Pro Forma Consolidated Information:	2012			2013
(in thousands)
Revenue	$	18,411		$	363
Net income (loss)	$	(49,807	)	$	(61,804	)

Goodwill (Tables)

12 Months Ended

Dec. 31, 2013

Goodwill

Schedule of changes in goodwill

The following table represents the changes in goodwill for the year ended December 31, 2013 (in thousands):


Balance at December 31, 2012	$	—
Goodwill related to the acquisition of Callidus (See Note 3)		11,613


Balance at December 31, 2013	$	11,613

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2013

Intangible Assets

Schedule representing the changes in IPR&D

The following table represents the changes in IPR&D for the year ended December 31, 2013 (in thousands):


Balance at December 31, 2012	$	—
IPR&D related to the acquisition of Callidus (See Note 3)		23,000


Balance at December 31, 2013	$	23,000

Cash, Money Market Funds and Marketable Securities (Tables)

12 Months Ended

Dec. 31, 2013

Cash, Money Market Funds and Marketable Securities

Schedule of cash and available for sale securities

Cash and available for sale securities consisted of the following as of December 31, 2012 and December 31, 2013 (in thousands):

	As of December 31, 2012

	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	33,971	$	—	$	—		$	33,971
Corporate debt securities		42,503		5		(11	)		42,497
Commercial paper		19,725		19		—			19,744
Certificate of deposit		2,909		1		—			2,910


	$	99,108	$	25	$	(11	)	$	99,122




Included in cash and cash equivalents	$	33,971	$	—	$	—		$	33,971
Included in marketable securities		65,137		25		(11	)		65,151


Total cash and marketable securities	$	99,108	$	25	$	(11	)	$	99,122

	As of December 31, 2013

	Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash balances	$	43,640	$	—	$	—		$	43,640
Corporate debt securities		30,817		1		(6	)		30,812
Commercial paper		7,192		6		—			7,198
Certificate of deposit		350		—		—			350


	$	81,999	$	7	$	(6	)	$	82,000




Included in cash and cash equivalents	$	43,640	$	—	$	—		$	43,640
Included in marketable securities		38,359		7		(6	)		38,360


Total cash and marketable securities	$	81,999	$	7	$	(6	)	$	82,000

Schedule of changes in AOCI associated with the unrealized holding gain on available-for-sale investments

The changes in AOCI associated with the unrealized holding gain on available-for-sale investments during the years ended December 31, 2012 and 2013, were as follows (in thousands):

	Year Ended December 31,

	2012		2013
Balance, beginning	$	4	$	14
Current period changes in fair value,^(a)		10		(13	)
Reclassification of earnings,^(a)		—		—


Balance, ending	$	14	$	1

(a): — Taxes have not been accrued on the unrealized gain on securities as the Company is in a loss position for all periods presented

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property and Equipment

Schedule of property and equipment

Property and equipment consist of the following (in thousands):

	December 31,

	2012			2013
Property and equipment consist of the following:
Computer equipment	$	3,399		$	3,537
Computer software		849			1,064
Research equipment		5,807			5,918
Furniture and fixtures		1,544			1,527
Leasehold improvements		1,931			2,047


		13,530			14,093
Less accumulated depreciation and amortization		(8,501	)		(9,973	)


	$	5,029		$	4,120

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2013

Accounts Payable and Accrued Expenses

Schedule of accounts payable and accrued expenses

Accounts payable and accrued expenses consist of the following (in thousands):

	December 31,

	2012		2013
Accounts payable	$	2,115	$	2,146
Accrued professional fees		409		498
Accrued contract manufacturing & contract research costs		1,743		1,499
Accrued compensation and benefits		4,229		4,781
Accrued facility costs		167		963
Accrued other		182		275


	$	8,845	$	10,162

Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2013

Stockholders' Equity

Summary of the stock compensation expense recognized in the statements of operations

The following table summarizes the stock compensation expense recognized in the statements of operations (in thousands):

	Years Ended December 31,

	2011		2012		2013
Stock compensation expense recognized in:
Research and development expense	$	2,928	$	3,603	$	3,583
General and administrative expense		5,751		2,588		2,594


Total stock compensation expense	$	8,679	$	6,191	$	6,177

Schedule of fair value weighted-average assumptions

	Years Ended December 31,

	2011			2012			2013
Expected stock price volatility		78.8	%		77.2	%		82.0	%
Risk free interest rate		2.0	%		0.8	%		1.3	%
Expected life of options (years)		6.25			6.25			6.25
Expected annual dividend per share	$	0.00		$	0.00		$	0.00

Summary of option activities

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Aggregate Intrinsic Value

	(in thousands)						(in thousands)
Options outstanding, December 31, 2010		5,104.1		$	7.27
Granted		2,217.0		$	5.92
Exercised		(108.5	)	$	3.88
Forfeited		(559.1	)	$	7.34


Options outstanding, December 31, 2011		6,653.5		$	6.87
Granted		2,846.6		$	5.34
Exercised		(437.0	)	$	3.73
Forfeited		(1,088.9	)	$	7.95


Options outstanding, December 31, 2012		7,974.2		$	6.35
Granted		2,481.8		$	3.04
Exercised		—			—
Forfeited		(1,414.9	)	$	5.01


Options outstanding, December 31, 2013		9,041.1		$	5.65	7.0 years	$	44.4




Vested and unvested expected to vest, December 31, 2013		8,637.7		$	5.73	6.9 years	$	43.3
Exercisable at December 31, 2013		5,502.7		$	6.68	5.8 years	$	38.5

Assets and Liabilities Measured at Fair Value (Tables)

12 Months Ended

Dec. 31, 2013

Assets and Liabilities Measured at Fair Value

Schedule of weighted average assumptions used in the Black-Scholes valuation model for the warrants

	December 31,

	2012			2013
Expected stock price volatility		93.2	%		45.9	%
Risk free interest rate		0.17	%		0.07	%
Expected life of warrants (years)		1.17			0.17
Expected annual dividend per share	$	0.00		$	0.00

Schedule of financial assets and liabilities subject to fair value measurements

	Level 1		Level 2		Total

*Assets:*
Cash/money market funds	$	33,971	$	—	$	33,971
Commercial paper		—		19,744		19,744
Corporate debt securities		—		42,497		42,497
Certificate of deposit		—		2,910		2,910


	$	33,971	$	65,151	$	99,122

	Level 1		Level 2		Level 3		Total

*Liabilities:*
Secured debt	$	—	$	697	$	—	$	697
Warrant liability		—		—		908		908


	$	—	$	697	$	908	$	1,605

	Level 1		Level 2		Total

*Assets:*
Cash/money market funds	$	43,640	$	—	$	43,640
Commercial paper		—		7,198		7,198
Corporate debt securities		—		30,812		30,812
Certificate of deposit		—		350		350


	$	43,640	$	38,360	$	82,000

	Level 1		Level 2		Level 3		Total

*Liabilities:*
Secured debt	$	—	$	14,473	$	—	$	14,473
Contingent success fee payable		—		—		264		264
Warrant liability		—		—		—		—
Contingent consideration payable		—		—		10,600		10,600


	$	—	$	14,473	$	10,864	$	25,337

Leases (Tables)

12 Months Ended

Dec. 31, 2013

Leases

Schedule of aggregate annual future minimum lease payments under the leases

At December 31, 2013, aggregate annual future minimum lease payments under these leases are as follows (in thousands):



Operating Leases
Years ending December 31:
2014	$	1,930
2015		2,033
2016		2,039
2017		1,769
2018 and beyond		2,074


	$	9,845

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income Taxes

Schedule of significant components of the deferred tax assets and liabilities

The significant components of the deferred tax assets and liabilities are as follows (in thousands):

	For Years Ended December 31,

	2012			2013
Current deferred tax asset
Non-cash stock issue	$	7,100		$	8,172
Others		1,257			1,343


		8,357			9,515
Non-current deferred tax assets
Amortization/depreciation		3,176			3,068
Research tax credit		9,072			13,680
Net operating loss carry forwards		62,060			79,984
Deferred revenue		12,149			14,649
Others		520			682


Gross deferred tax assets		95,334			121,578
Deferred tax liability related to business acquisition		—			(9,186	)


Total net deferred tax asset		95,334			112,392
Less valuation allowance		(95,334	)		(121,578	)


Net deferred tax assets (liability)	$	—		$	(9,186	)

Schedule of reconciliation of the statutory tax rates and the effective tax rates

	Years Ended December 31,

	2011			2012			2013
Statutory rate		(34	)%		(34	)%		(34	)%
State taxes, net of federal benefit		(13	)		(3	)		(5	)
Permanent adjustments		3			—			(1	)
R&D credit		—			(8	)		(3	)
Other		2			1			—
Valuation allowance		34			38			37


Net		(8	)%		(6	)%		(6	)%

Short-Term Borrowings and Long-Term Debt (Tables)

12 Months Ended

Dec. 31, 2013

Short-Term Borrowings and Long-Term Debt

Schedule of remaining future minimum payments of principal due

The remaining future minimum payments of principal due as of December 31, 2013 are as follows (in thousands):


Years ending December 31:
2014	$	299
2015		4,035
2016		5,443
2017		5,522
2018 and beyond		—


Total principal obligation		15,299
Less short-term portion		(299	)


Long-term portion, gross of debt discount		15,000
Less debt discount		(826	)


Long term portion, net of debt discount	$	14,174

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

+ Details

Restructuring Charges (Tables)

12 Months Ended

Dec. 31, 2013

Restructuring Charges

Summary of restructuring charges and utilization

The following table summarizes the restructuring charges and utilization for the year ended December 31, 2013 (in thousands):

	Balance as of December 31, 2012		Charges		Cash Payments			Adjustments		Balance as of December 31, 2013

Employment termination costs	$	—	$	1,227	$	(88	)	$	—	$	1,139
Facilities consolidation		—		703		—			—		703
Property and equipment disposal		—		58		—			—		—


Total	$	—	$	1,988	$	(88	)	$	—	$	1,842

Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Tables)

12 Months Ended

Dec. 31, 2013

Selected Quarterly Financial Data (Unaudited - in thousands except per share data)

Schedule of selected quarterly financial data

	Quarters Ended

	March 31			June 30			September 30			December 31
2012
Net loss		(13,137	)		(9,343	)		(16,290	)		(10,015	)
Basic and diluted net loss per common share ⁽¹⁾		(0.35	)		(0.20	)		(0.34	)		(0.20	)
2013
Net loss		(17,458	)		(15,349	)		(14,589	)		(12,237	)
Basic and diluted net loss per common share ⁽¹⁾		(0.35	)		(0.31	)		(0.29	)		(0.22	)

(1): Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not add to the annual amounts because of differences on the weighted-average common shares outstanding during each period principally due to the effect of the Company issuing shares of its common stock during the year.

Description of Business (Details) $ in Thousands	1 Months Ended					12 Months Ended		143 Months Ended
Description of Business (Details) $ in Thousands	Nov. 30, 2013 USD ($) item $ / shares shares	Jul. 31, 2012 USD ($) shares	Mar. 31, 2012 USD ($) shares	Oct. 31, 2010 USD ($) shares	Mar. 31, 2010 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) $ / shares	Dec. 31, 2012 USD ($)	Dec. 31, 2013 USD ($) $ / shares
Corporate Information, Status of Operations and Management Plans
Stock issued from collaboration agreement (in shares)					4,950,000
Warrant term					4 years
Exercise price of warrants (in dollars per share) \| $ / shares					4.43
Aggregate offering proceeds \| $					$ 17,100
Proceeds received from private placement \| $	$ 15,000
Accumulated deficit \| $						$ 378,522	$ 318,889	$ 378,522
Common stock issued (in shares)	7,500,000		11,500,000		4,950,000
Warrants issued (in shares)	1,600,000				1,900,000
Proceeds from the issuance of common stock (in dollars) \| $			$ 62,000			15,000	$ 80,195	$ 208,441
SPA
Corporate Information, Status of Operations and Management Plans
Exercise price of warrants (in dollars per share) \| $ / shares	2.50
Aggregate offering proceeds \| $						$ 15,000
Proceeds received from private placement \| $	$ 15,000
GSK \| Original Collaboration Agreement
Corporate Information, Status of Operations and Management Plans
Stock issued from collaboration agreement (in shares)				6,870,000
Proceeds from the issuance of common stock (in dollars) \| $				$ 31,000
GSK \| Expanded Collaboration Agreement
Corporate Information, Status of Operations and Management Plans
Common stock issued (in shares)		2,900,000
Proceeds from the issuance of common stock (in dollars) \| $		$ 18,600
GSK \| SPA
Corporate Information, Status of Operations and Management Plans
Stock issued from collaboration agreement (in shares)	1,500,000	2,900,000
Warrant term						1 year
Exercise price of warrants (in dollars per share) \| $ / shares						2.50		2.50
Equity stake in the Company (as a percent)						17.60%		17.60%
Warrants issued (in shares)	1,600,000
GSK \| Revised Agreement
Corporate Information, Status of Operations and Management Plans
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive single-digit royalties on net sales \| item	8
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones \| item	8
Redmile Group \| SPA
Corporate Information, Status of Operations and Management Plans
Stock issued from collaboration agreement (in shares)	6,000,000
Number of shares represented by units issued	6,000,000

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2013
Minimum
Property and Equipment
Estimated useful lives	3 years
Maximum
Property and Equipment
Estimated useful lives	5 years

Summary of Significant Accounting Policies (Details 2)	Dec. 31, 2013 item
Stock-Based Compensation
Number of stock-based employee compensation plans	3

Summary of Significant Accounting Policies (Details 3) $ in Thousands	12 Months Ended			143 Months Ended
	Dec. 31, 2013 USD ($) item shares	Dec. 31, 2012 USD ($) shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2013 USD ($)
Numerator:
Net loss attributable to common stockholders \| $	$ (59,633)	$ (48,785)	$ (44,412)	$ (398,748)
Denominator
Weighted average common shares outstanding - basic and diluted	51,286,059	45,565,217	34,569,642
Segment Information
Number of business segments \| item	1
Common stock options
Antidilutive securities
Antidilutive securities excluded from computation of diluted earnings per share (in shares)	12,000,000	9,400,000	8,500,000

Acquisition of Callidus Biopharma, Inc. (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Acquisition of Callidus Biopharma, Inc.
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01
Allocation of the purchase consideration, including the contingent acquisition consideration payable
Contingent acquisition consideration payable		$ 10,600
Goodwill		11,613
Unaudited Pro Forma Consolidated Information:
Revenue		363	$ 18,411
Net income (loss)		$ (61,804)	$ (49,807)
Callidus
Acquisition of Callidus Biopharma, Inc.
Common stock issued on acquisition (in shares)	7.2	2.4
Common stock, par value (in dollars per share)	$ 0.01
Shares issued		4.8
Maximum merger consideration to be transferred	$ 130,000
Milestone payment that can be settled in equity	$ 40,000
Number of trading days immediately preceding the date of payment on basis of which issue price will be determined	10 days
Discount rate (as a percent)	13.50%
Allocation of the purchase consideration, including the contingent acquisition consideration payable
Upfront equity payments	$ 15,000
Contingent acquisition consideration payable	10,600
Total consideration	25,600
Cash and cash equivalents	34
Property, plant and equipment	173
Intangible assets-(IPR&D)	23,000
Total identifiable assets acquired	23,207
Accounts payable	(34)
Deferred tax liability	(9,186)
Total liabilities assumed	(9,220)
Net identifiable assets acquired	13,987
Goodwill	11,613
Net assets acquired	25,600
Deferred tax liabilities relates to the tax impact of future amortization or possible impairments associated with identified intangible assets acquired	9,200
Acquisition-related transaction costs		$ 500
Callidus \| Maximum
Acquisition of Callidus Biopharma, Inc.
Additional payment to be made upon achievement of clinical milestone	35,000
Additional payment to be made upon achievement of regulatory approval	$ 105,000

Goodwill (Details) $ in Thousands	12 Months Ended
Goodwill (Details) $ in Thousands	Dec. 31, 2013 USD ($)
Goodwill
Impairment of goodwill	$ 0
Changes in goodwill
Goodwill related to the acquisition of Callidus (See Note 3)	11,613
Balance at end of the period	$ 11,613

Intangible Assets (Details) $ in Thousands	12 Months Ended
Intangible Assets (Details) $ in Thousands	Dec. 31, 2013 USD ($)
Intangible Assets
Impairment of IPR&D	$ 0
Changes in IPR&D
IPR&D related to the acquisition of Callidus	23,000
Balance at the end of the period	$ 23,000

Cash, Money Market Funds and Marketable Securities (Details) - USD ($) $ in Thousands	12 Months Ended										143 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005	Dec. 31, 2004	Dec. 31, 2013
Cash, Money Market Funds, and Marketable Securities
Cash and cash equivalents, Amortized Cost	$ 43,640	$ 33,971	$ 25,668	$ 29,572							$ 43,640
Cash and cash equivalents, Fair Value	43,640	33,971									43,640
Marketable securities, Amortized Cost	38,359	65,137									38,359
Unrealized Gain	7	25									7
Unrealized Loss	(6)	(11)									(6)
Marketable securities, Fair Value	38,360	65,151									38,360
Cash and marketable securities, Amortized Cost	81,999	99,108									81,999
Cash and marketable securities, Fair Value	82,000	99,122									82,000
Available-for-sale investments
Realized gain (loss) on securities available-for-sale	0	0
Fair value of available for sale securities in unrealized loss positions	23,600	33,100									23,600
Changes in AOCI associated with the unrealized holding gain on available-for-sale investments
Balance, beginning	14	4
Current period changes in fair value	(13)	10	32	$ (71)	$ (490)	$ 125	$ 393	$ 31	$ (7)	$ (9)	1
Balance, ending	1	14	$ 4								1
Corporate debt securities
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	30,817	42,503									30,817
Unrealized Gain	1	5									1
Unrealized Loss	(6)	(11)									(6)
Marketable securities, Fair Value	30,812	42,497									30,812
Commercial paper
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	7,192	19,725									7,192
Unrealized Gain	6	19									6
Marketable securities, Fair Value	7,198	19,744									7,198
Certificate of deposit
Cash, Money Market Funds, and Marketable Securities
Marketable securities, Amortized Cost	350	2,909									350
Unrealized Gain		1
Marketable securities, Fair Value	$ 350	$ 2,910									$ 350

Property and Equipment (Details) - USD ($)	12 Months Ended			143 Months Ended
Property and Equipment (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Property and Equipment
Property and equipment, gross	$ 14,093,000	$ 13,530,000		$ 14,093,000
Less accumulated depreciation and amortization	(9,973,000)	(8,501,000)		(9,973,000)
Property and equipment, net	4,120,000	5,029,000		4,120,000
Depreciation and amortization expense	1,719,000	1,705,000	$ 1,585,000	13,487,000
Capital lease obligations outstanding	0			0
Computer equipment
Property and Equipment
Property and equipment, gross	3,537,000	3,399,000		3,537,000
Computer software
Property and Equipment
Property and equipment, gross	1,064,000	849,000		1,064,000
Research equipment
Property and Equipment
Property and equipment, gross	5,918,000	5,807,000		5,918,000
Furniture and fixtures
Property and Equipment
Property and equipment, gross	1,527,000	1,544,000		1,527,000
Leasehold improvements
Property and Equipment
Property and equipment, gross	2,047,000	1,931,000		2,047,000
Property and equipment that are under capital lease obligation
Property and Equipment
Depreciation and amortization expense	$ 1,700,000	$ 1,700,000		$ 13,500,000

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Accrued expenses
Accounts payable	$ 2,146	$ 2,115
Accrued professional fees	498	409
Accrued contract manufacturing & contract research costs	1,499	1,743
Accrued compensation and benefits	4,781	4,229
Accrued facility costs	963	167
Accrued other	275	182
Accounts payable and accrued expenses	$ 10,162	$ 8,845

Stockholders' Equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended			143 Months Ended
	Nov. 30, 2013 USD ($) $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Mar. 31, 2012 USD ($) $ / shares shares	Oct. 31, 2010 USD ($) $ / shares shares	Mar. 31, 2010 USD ($) $ / shares shares	Dec. 31, 2013 USD ($) item $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2010 USD ($)	Dec. 31, 2013 USD ($) item $ / shares shares
Stockholders' Equity
Authorized number of shares of common stock						125,000,000	125,000,000		125,000,000
Voting right for each share held, number \| item						1			1
Collaborative Agreements
Stock issued from collaboration agreement (in shares)					4,950,000
Common stock issued (in shares)	7,500,000		11,500,000		4,950,000
Offering price (in dollars per share) \| $ / shares			$ 5.70		$ 3.74	$ 2.12			$ 2.12
Total purchase price (in dollars) \| $							$ 18,140	$ 28,083
Aggregate offering proceeds from issuance of common stock (in dollars) \| $			$ 65,600		$ 18,500
Common stock, par value (in dollars per share) \| $ / shares						$ 0.01	$ 0.01		$ 0.01
Number of shares of common stock sold in a unit					1
Number of warrants sold in a unit (in shares)					1
Warrants issued (in shares)	1,600,000				1,900,000
Exercise price of warrants (in dollars per share) \| $ / shares					4.43
Proceeds received from private placement \| $	$ 15,000
Number of inputs used to determine the value of the warrants \| item						6
Remaining term of the warrants						2 months 1 day	1 year 2 months 1 day
Volatility (as a percent)						45.90%	93.20%
Annual rate of dividends (as a percent)						0.00%	0.00%
Riskless rate of return (as a percent)						0.07%	0.17%
Warrants outstanding (in shares)						1,400,000			1,400,000
Portion of share purchased against a unit					0.375
Warrant term					4 years
Exercise period of warrants on or after date of issue					6 months
Proceeds from the issuance of common stock and warrants (in dollars) \| $			$ 62,000			$ 15,000	$ 80,195		$ 208,441
Warrants
Collaborative Agreements
Exercise price of warrants (in dollars per share) \| $ / shares						$ 2.50			$ 2.50
Remaining term of the warrants						1 year
Volatility (as a percent)						93.50%
Annual rate of dividends (as a percent)						0.00%
Riskless rate of return (as a percent)						0.12%
Value of the warrants \| $						$ 1,000
Maximum
Collaborative Agreements
Fair value of the warrant liability \| $						$ 1			$ 1
Callidus
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Common stock issued on acquisition (in shares)	7,200,000					2,400,000
Shares issued						4,800,000
SPA
Collaborative Agreements
Common stock, par value (in dollars per share) \| $ / shares	$ 0.01
Exercise price of warrants (in dollars per share) \| $ / shares	2.50
Proceeds received from private placement \| $	$ 15,000
GSK \| SPA
Collaborative Agreements
Stock issued from collaboration agreement (in shares)	1,500,000	2,900,000
Offering price (in dollars per share) \| $ / shares	$ 2.00	$ 6.30
Total purchase price (in dollars) \| $		$ 18,600
Warrants issued (in shares)	1,600,000
Exercise price of warrants (in dollars per share) \| $ / shares						2.50			2.50
Equity stake in the Company (as a percent)						17.60%			17.60%
Warrant term						1 year
GSK \| Original Collaboration Agreement
Collaborative Agreements
Stock issued from collaboration agreement (in shares)				6,870,000
Offering price (in dollars per share) \| $ / shares				$ 4.56
Proceeds from the issuance of common stock and warrants (in dollars) \| $				$ 31,000
Redmile Group \| SPA
Collaborative Agreements
Stock issued from collaboration agreement (in shares)	6,000,000
Number of shares represented by units issued	6,000,000
Price per unit (in dollars per share) \| $ / shares	$ 2.00
Number of shares of common stock sold in a unit	1
Number of warrants sold in a unit (in shares)	0.267

Stockholders' Equity (Details 2)	12 Months Ended
Stockholders' Equity (Details 2)	Dec. 31, 2013 shares
Stock options
Stockholders' Equity
Maximum term of option	10 years
2007 Director Plan \| Stock options
Stockholders' Equity
Maximum term of option	10 years
2002 Plan and 2007 Plan \| Stock options
Stockholders' Equity
Percentage of options vest on the first year anniversary	25.00%
Additional percentage of options that will vest each month after first anniversary	2.08%
Percentage of shares vested that may be exercised in whole or part	100.00%
2007 Plan and 2007 Director Plan \| Maximum \| Stock options
Stockholders' Equity
Number of shares reserved for issuance	2,508,411
2002 Plan
Stockholders' Equity
Number of shares reserved for issuance	0

Stockholders' Equity (Details 3) - USD ($) $ in Thousands	12 Months Ended
Stockholders' Equity (Details 3) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock compensation expense
Total stock compensation expense	$ 6,177	$ 6,191	$ 8,679
Research and development expense
Stock compensation expense
Total stock compensation expense	3,583	3,603	2,928
General and administrative expense
Stock compensation expense
Total stock compensation expense	$ 2,594	$ 2,588	$ 5,751

Stockholders' Equity (Details 4) - USD ($)	12 Months Ended
Stockholders' Equity (Details 4) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stockholders' Equity
Minimum stock price volatility (as a percent)	75.00%
Stock options plans
Fair value weighted-average assumptions:
Expected stock price volatility (as a percent)	82.00%	77.20%	78.80%
Risk free interest rate (as a percent)	1.30%	0.80%	2.00%
Expected life of options	6 years 3 months	6 years 3 months	6 years 3 months
Expected annual dividend per share (in dollars per share)	$ 0.00	$ 0.00	$ 0.00
Weighted-average grant-date fair value per share of options granted (in dollars per share)	$ 2.14	$ 3.31	$ 4.11
Number of Shares
Balance at the beginning of the period (in shares)	7,974,200	6,653,500	5,104,100
Options granted (in shares)	2,481,800	2,846,600	2,217,000
Options exercised (in shares)	0	(437,000)	(108,500)
Options forfeited (in shares)	(1,414,900)	(1,088,900)	(559,100)
Balance at the end of the period (in shares)	9,041,100	7,974,200	6,653,500
Vested and unvested expected to vest at the end of the period (in shares)	8,637,700
Exercisable at the end of the period (in shares)	5,502,700
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 6.35	$ 6.87	$ 7.27
Options granted (in dollars per share)	3.04	5.34	5.92
Options exercised (in dollars per share)		3.73	3.88
Options forfeited (in dollars per share)	5.01	7.95	7.34
Balance at the end of the period (in dollars per share)	5.65	$ 6.35	$ 6.87
Vested and unvested expected to vest at the end of the period (in dollars per share)	5.73
Exercisable at the end of the period (in dollars per share)	$ 6.68
Weighted Average Remaining Contractual Life
Balance at the end of the period	7 years
Vested and unvested expected to vest at the end of the period	6 years 10 months 24 days
Exercisable at the end of the period	5 years 9 months 18 days
Aggregate Intrinsic Value
Aggregate intrinsic value of options outstanding (in dollars)	$ 44,400
Aggregate intrinsic value of options vested and unvested expected to vest (in dollars)	43,300
Aggregate intrinsic value of options exercisable (in dollars)	$ 38,500
Aggregate intrinsic value of options exercised (in dollars)		$ 900,000	$ 300,000
Options exercised (in shares)	0	(437,000)	(108,500)
Total unrecognized compensation cost related to non-vested stock options granted (in dollars)	$ 7,300,000
Period of recognition compensation cost	2 years 3 months 18 days
Cash proceeds from stock options exercised (in dollars)		$ 1,600,000	$ 400,000
Restricted stock
Aggregate Intrinsic Value
Number of shares surrendered to fund minimum statutory tax withholding requirements			13,225
Restricted stock awards (in shares)	0	0	0
Unrecognized compensation cost related to unvested restricted stock awards (in dollars)	$ 0
Amount of net operating loss carry forwards			$ 400,000

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands, shares in Millions	1 Months Ended	12 Months Ended		143 Months Ended
	Mar. 31, 2010 USD ($)	Dec. 31, 2013 USD ($) item	Dec. 31, 2012 USD ($) shares	Dec. 31, 2013 USD ($)	Nov. 30, 2013 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Assets and Liabilities Measured at Fair Value
Transfer of assets from Level 1 to Level 2		$ 0		$ 0
Transfer of assets from Level 2 to Level 1		$ 0		0
Number of inputs used in fair value classification \| item		6
Warrant liability		$ 0		0
Weighted average assumptions used in the Black-Scholes valuation model for the warrants
Expected stock price volatility (as a percent)		45.90%	93.20%
Risk free interest rate (as a percent)		0.07%	0.17%
Expected life of warrants		2 months 1 day	1 year 2 months 1 day
Expected annual dividend per share (as a percent)		0.00%	0.00%
Financial assets and liabilities subject to fair value measurements
Proceeds from issuance of warrants		$ 1,046		1,046
Assets:
Cash/money market fund		43,640	$ 33,971	43,640		$ 25,668	$ 29,572
Liabilities:
Warrant liability		0		0
Contingent consideration payable		10,600		10,600
Changes in Level 3 liability
Increase/(Decrease) in fair value		10,000	(700)
Settlement amount received upon exercise of warrants			$ 300
Warrants exercised (in shares) \| shares			0.5
Addition of contingent consideration payable		10,600
Decrease in fair value of the warrant liability		(900)
Callidus
Liabilities:
Contingent consideration payable					$ 10,600
SPA
Financial assets and liabilities subject to fair value measurements
Proceeds from issuance of warrants	$ 3,300
Level 1
Assets:
Cash/money market fund		43,640	$ 33,971	43,640
Fair value of assets		43,640	33,971	43,640
Level 2
Assets:
Fair value of assets		38,360	65,151	38,360
Liabilities:
Secured debt		14,473	697	14,473
Fair value of liabilities		14,473	697	14,473
Level 2 \| Commercial paper
Assets:
Fair value of assets		7,198	19,744	7,198
Level 2 \| Corporate debt securities
Assets:
Fair value of assets		30,812	42,497	30,812
Level 2 \| Certificate of deposit
Assets:
Fair value of assets		350	2,910	350
Level 3
Assets and Liabilities Measured at Fair Value
Warrant liability			908
Liabilities:
Contingent success fee payable		264		264
Warrant liability			908
Contingent consideration payable		10,600		10,600
Fair value of liabilities		10,864	908	10,864
Total
Assets and Liabilities Measured at Fair Value
Warrant liability			908
Assets:
Cash/money market fund		43,640	33,971	43,640
Fair value of assets		82,000	99,122	82,000
Liabilities:
Secured debt		14,473	697	14,473
Contingent success fee payable		264		264
Warrant liability			908
Contingent consideration payable		10,600		10,600
Fair value of liabilities		25,337	1,605	25,337
Total \| Commercial paper
Assets:
Fair value of assets		7,198	19,744	7,198
Total \| Corporate debt securities
Assets:
Fair value of assets		30,812	42,497	30,812
Total \| Certificate of deposit
Assets:
Fair value of assets		350	$ 2,910	350
2013 Loan Agreement
Financial assets and liabilities subject to fair value measurements
Fair value of contingent payment		$ 300
Period of trigger event within which success fee is payable		6 months
Period of effectiveness of trigger event from closing of loan		5 years
2013 Loan Agreement \| Level 3
Liabilities:
Contingent success fee payable		$ 300		300
2013 Loan Agreement \| Maximum \| Level 3
Liabilities:
Contingent success fee payable		$ 400		$ 400

401(k) Plan (Details) - USD ($) $ in Millions	12 Months Ended
401(k) Plan (Details) - USD ($) $ in Millions	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
401 (k) Plan
Maximum contribution by the company as a percentage of employee's salary and bonus paid during the year	5.00%
Total contribution to the plan (in dollars)	$ 0.7	$ 0.7	$ 0.6

Leases (Details) $ in Thousands	12 Months Ended
Leases (Details) $ in Thousands	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($) ft² item
Operating Leases
Area of laboratory and office space leased (in square feet) \| ft²			73,646
Initial term of the lease agreement			7 years
Number of times lease term may be extended \| item			2
Extended additional term of lease agreement			5 years
Annual future minimum lease payments
2014	$ 1,930
2015	2,033
2016	2,039
2017	1,769
2018 and beyond	2,074
Total	9,845
Rent expense	$ 2,600	$ 2,600	$ 2,300

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current deferred tax asset
Non-cash stock issue	$ 8,172	$ 7,100
Others	1,343	1,257
Total current deferred tax asset	9,515	8,357
Non-current deferred tax assets
Amortization/depreciation	3,068	3,176
Research tax credit	13,680	9,072
Net operating loss carry forwards	79,984	62,060
Deferred revenue	14,649	12,149
Others	682	520
Gross deferred tax assets	121,578	95,334
Deferred tax liability related to business acquisition	(9,186)
Total net deferred tax asset	112,392	95,334
Less valuation allowance	(121,578)	(95,334)
Net deferred tax assets (liability)	(9,186)
Increase in the valuation allowance	$ 26,300	$ 20,100

Income Taxes (Details 2) $ in Millions	12 Months Ended
Income Taxes (Details 2) $ in Millions	Dec. 31, 2013 USD ($)
Net operating loss carry forwards
Maximum change in ownership percentage allowed before statutory limitations imposed on the availability of net operating losses	50.00%
Period for measuring the change in ownership	3 years
Tax benefit associated with exercise of stock options to be recorded in additional paid-in capital on recognition of associated NOL	$ 2.0
Federal
Net operating loss carry forwards
Amount of net operating loss carry forwards	203.8
State
Net operating loss carry forwards
Amount of net operating loss carry forwards	$ 179.9

Income Taxes (Details 3) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Details 3) - USD ($) $ in Millions	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of the statutory tax rates and the effective tax rates
Statutory rate (as a percent)	(34.00%)	(34.00%)	(34.00%)
State taxes, net of federal benefit (as a percent)	(5.00%)	(3.00%)	(13.00%)
Permanent adjustments (as a percent)	(1.00%)		3.00%
R&D credit (as a percent)	(3.00%)	(8.00%)
Other (as a percent)		1.00%	2.00%
Valuation allowance (as a percent)	37.00%	38.00%	34.00%
Net (as a percent)	(6.00%)	(6.00%)	(8.00%)
Income tax benefit from the sale of net operating losses and research and development credits	$ 3.5	$ 3.2	$ 3.6

Licenses (Details)	1 Months Ended			12 Months Ended
Licenses (Details)	Aug. 31, 2012 USD ($)	Nov. 30, 2007 USD ($)	Apr. 30, 2002 shares	Dec. 31, 2013 USD ($) item	Dec. 31, 2010 USD ($)	Dec. 31, 2008 USD ($)	Dec. 31, 2006 USD ($) shares
Licenses
Estimated fair value of stock issued in connection with the amendment to license agreement for license payment							$ 1,220,000
MSSM
Licenses
Upfront and annual license fees paid				$ 0
Potential milestone payments				$ 0
License agreement
Licenses
Number of licensors to whom the entity would expect to pay royalties \| item				3
License agreement \| MSSM
Licenses
Stock issued for in-process research and development (in shares) \| shares			232,266
Amount paid in connection with the amendment to license agreement for license payment							$ 1,000,000
Stock issued in connection with the amendment to license agreement for license payment (in shares) \| shares							133,333
Estimated fair value of stock issued in connection with the amendment to license agreement for license payment							$ 1,200,000
Total research and development expense in connection with the amendment							$ 2,200,000
Amount paid by the company in connection with the upfront payment received		$ 2,600,000			$ 3,000,000
Additional amount paid for the sole right to and control over the prosecution of patent rights						$ 2,600,000
Amount paid by the company in connection with the milestone payment received	$ 350,000
License agreement \| MSSM \| GSK
Licenses
Upfront payment received					$ 30,000,000
Milestone payment received	$ 3,500,000
License agreement \| MSSM \| Shire
Licenses
Upfront payment received						$ 50,000,000
License agreement \| University of Maryland, Baltimore County
Licenses
Upfront and annual license fees paid				$ 45,000
License agreement \| University of Maryland, Baltimore County \| Maximum
Licenses
Potential milestone payments				200,000
License agreement \| Novo Nordisk A/S
Licenses
Upfront and annual license fees paid				400,000
Potential milestone payments				$ 7,800,000

Collaborative Agreements (Details) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended					3 Months Ended	12 Months Ended				143 Months Ended
	Nov. 30, 2013 USD ($) item $ / shares shares	Jul. 31, 2012 USD ($) $ / shares shares	Mar. 31, 2012 USD ($) $ / shares	Oct. 31, 2010 USD ($) $ / shares shares	Mar. 31, 2010 $ / shares shares	Jun. 30, 2012 USD ($)	Dec. 31, 2013 USD ($) item $ / shares	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2013 USD ($) $ / shares
Collaborative Agreements
Stock issued from collaboration agreement (in shares) \| shares					4,950
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) \| $ / shares			$ 5.70		$ 3.74		$ 2.12				$ 2.12
Total value of the equity investment to the company			$ 62,000				$ 15,000	$ 80,195			$ 208,441
Total purchase price (in dollars)								18,140		$ 28,083
Research revenue for work performed under cost sharing arrangement							$ 363	$ 11,591	$ 14,794		$ 57,856
GSK
Collaborative Agreements
Milestone revenue recognized						$ 3,500
Number of accounting units \| item							1
GSK \| Original Collaboration Agreement
Collaborative Agreements
Upfront payment received				$ 30,000
Potential milestone payments receivable				173,500
Potential milestone payments receivable				13,500
Potential milestone payments receivable				80,000
Potential milestone payments receivable				$ 80,000
Stock issued from collaboration agreement (in shares) \| shares				6,870
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) \| $ / shares				$ 4.56
Percentage of premium on average price per share of common stock issued as part of the license and collaboration agreement				30.00%
Period preceding the closing date of the transaction over which average price per share of the company's stock is used				60 days
Total value of the equity investment to the company				$ 31,000
GSK \| Expanded Collaboration Agreement
Collaborative Agreements
Total value of the equity investment to the company		$ 18,600
GSK \| SPA
Collaborative Agreements
Stock issued from collaboration agreement (in shares) \| shares	1,500	2,900
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) \| $ / shares	$ 2.00	$ 6.30
Total purchase price (in dollars)		$ 18,600
GSK \| Revised Agreement
Collaborative Agreements
Upfront payment received	$ 0
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive single-digit royalties on net sales \| item	8
Number of major markets outside the U.S. from whom parties to contractual arrangement is eligible to receive post-approval and sales-based milestones \| item	8
GSK \| Revised Agreement \| Maximum
Collaborative Agreements
Potential milestone payments upon achievement of post-approval and sales-based milestones	$ 40,000
Biogen Idec
Collaborative Agreements
Research revenue for work performed under cost sharing arrangement							$ 400

Short-Term Borrowings and Long-Term Debt (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Dec. 31, 2013 USD ($) item	Feb. 29, 2012 USD ($)	Dec. 31, 2013 USD ($) item	Dec. 31, 2012 USD ($)
Short-Term Borrowings and Long-Term Debt
Long-term portion, gross of debt discount	$ 15,000		$ 15,000
Less debt discount	826		826
Remaining future minimum payments of principal due
2014	299		299
2015	4,035		4,035
2016	5,443		5,443
2017	5,522		5,522
Total principal obligation	15,299		15,299
Less short-term portion	(299)		(299)	$ (398)
Long-term portion, gross of debt discount	15,000		15,000
Less debt discount	(826)		(826)
Long term portion, net of debt discount	14,174		14,174	$ 299
Level 3
Short-Term Borrowings and Long-Term Debt
Contingent success fee payable	264		264
2011 Loan Agreement
Short-Term Borrowings and Long-Term Debt
Maximum amount of loan	3,000		3,000
Long-term portion, gross of debt discount	$ 300		$ 300
Variable interest rate base, SVB prime rate			SVB prime
Percentage points added to the reference rate			2.50%
SVB prime rate (as a percent)	4.00%		4.00%
Amount borrowed		$ 1,000
Period for repayment of debt		2 years 6 months
Remaining future minimum payments of principal due
Long-term portion, gross of debt discount	$ 300		$ 300
2013 Loan Agreement
Short-Term Borrowings and Long-Term Debt
Maximum amount of loan	$ 25,000		$ 25,000
Fixed interest rate (as a percent)	8.50%		8.50%
Long-term portion, gross of debt discount	$ 15,000		$ 15,000
Amount borrowed	15,000
Less debt discount	$ 800		$ 800
Number of equal monthly installments for repayment of debt \| item	33		33
Debt facility fee	$ 100		$ 100
Contingent exit fee payable	400		400
Fair value of contingent payment			$ 300
Period of trigger event within which success fee is payable			6 months
Period of effectiveness of trigger event from closing of loan			5 years
Remaining future minimum payments of principal due
Long-term portion, gross of debt discount	15,000		$ 15,000
Less debt discount	(800)		(800)
2013 Loan Agreement \| Level 3
Short-Term Borrowings and Long-Term Debt
Contingent success fee payable	300		300
2013 Loan Agreement \| Maximum [Member]
Short-Term Borrowings and Long-Term Debt
Amount available for borrowing	10,000		10,000
2013 Loan Agreement \| Maximum [Member] \| Level 3
Short-Term Borrowings and Long-Term Debt
Contingent success fee payable	$ 400		$ 400

Restructuring Charges (Details) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended			143 Months Ended
Restructuring Charges (Details) $ in Thousands	Dec. 31, 2013 USD ($) item	Nov. 30, 2013 item	Dec. 31, 2013 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2013 USD ($)
Restructuring charges
Restructuring charges			$ 1,900	$ 1,988			$ 3,510
Lease payments				2,600	$ 2,600	$ 2,300
Summary of restructuring charges and utilization
Charges			(1,900)	(1,988)			(3,510)
Cash Payments				(88)
Balance at the end of the period	$ 1,842		1,842	$ 1,842			1,842
Period within which employee termination costs will be paid				1 year
Employment termination costs
Restructuring charges
Employees eliminated (as a percent)		14.00%
Number of employees eliminated \| item		15
Restructuring charges			1,200	$ (1,227)
Restructuring charges unpaid and classified under accrued expenses	1,100		1,100	1,100			1,100
Summary of restructuring charges and utilization
Charges			(1,200)	1,227
Cash Payments				(88)
Balance at the end of the period	$ 1,139		1,139	1,139			1,139
Facilities consolidation
Restructuring charges
Number of subleased locations that were closed in consolidation \| item	1
Restructuring charges			800	(703)
Lease payments			700
Write-down of the net book value of fixed assets			100
Summary of restructuring charges and utilization
Charges			(800)	703
Balance at the end of the period	$ (703)		$ (703)	(703)			$ (703)
Property and equipment disposal
Restructuring charges
Restructuring charges				(58)
Summary of restructuring charges and utilization
Charges				$ 58

Selected Quarterly Financial Data (Unaudited - in thousands except per share data) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								11 Months Ended	12 Months Ended											143 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2002	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007	Dec. 31, 2006	Dec. 31, 2005	Dec. 31, 2004	Dec. 31, 2003	Dec. 31, 2013
Selected Quarterly Financial Data
Net loss	$ (12,237)	$ (14,589)	$ (15,349)	$ (17,458)	$ (10,015)	$ (16,290)	$ (9,343)	$ (13,137)	$ (1,775)	$ (59,633)	$ (48,785)	$ (44,412)	$ (54,936)	$ (6,567)	$ (39,355)	$ (41,167)	$ (46,345)	$ (19,972)	$ (8,807)	$ (6,768)	$ (378,522)
Basic and diluted net loss per common share (in dollars per share)	$ (0.22)	$ (0.29)	$ (0.31)	$ (0.35)	$ (0.20)	$ (0.34)	$ (0.20)	$ (0.35)		$ (1.16)	$ (1.07)	$ (1.28)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Label	Element	Value
Adjustments to Additional Paid in Capital Share Based Compensation Requisite Service Period Recognition Value Amortization	fold_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueAmortization	$ 27,000
Stock Issued for in Process Research and Development	fold_StockIssuedForInProcessResearchAndDevelopment	418,000
Adjustments to Additional Paid in Capital, Warrant Issued	us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	84,000
Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock	us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	$ 11,000
Common Stock [Member]
Stock Issued During Period, Shares, Research and Development	fold_StockIssuedDuringPeriodSharesResearchAndDevelopment	232,266
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	74,938
Stock Issued for in Process Research and Development	fold_StockIssuedForInProcessResearchAndDevelopment	$ 17,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	6,000
Additional Paid-in Capital [Member]
Stock Issued for in Process Research and Development	fold_StockIssuedForInProcessResearchAndDevelopment	401,000
Adjustments to Additional Paid in Capital, Warrant Issued	us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued	8,000
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	78,000
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	209,000
Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock	us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	11,000
Retained Earnings [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(1,775,000)
Deferred Compensation, Share-based Payments [Member]
Adjustments to Additional Paid in Capital Share Based Compensation Requisite Service Period Recognition Value Amortization	fold_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueAmortization	27,000
Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	$ (209,000)